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Abstract. 
Oligodendrocyte precursor cells (OPCs), also known as NG2 cells, are widespread in the grey 
and white matter regions throughout the entire central nervous system. OPCs express functional 
3-hydroxy-5-methyl-4-isoxazolepropionate receptors (AMPARs) and receive glutamatergic 
synaptic input from neurons. Transition of OPCs to the pre-myelinating stage is accompanied by 
the rapid removal of glutamatergic synaptic input, including downregulation of AMPARs. 
However, the functional role of AMPARs mediated synaptic signaling between neurons and 
OPCs remains unclear. The goal of my study was to alter the AMPARs mediated signaling 
between neurons and OPCs in the mouse corpus callosum in vivo, and to study the consequences 
of these alterations for proliferation and differentiation of OPCs. To reach this goal, I perturbed 
the properties of GluA2-containing AMPARs in callosal OPCs during the 2-3 postnatal weeks. 
Expression of Ca
2+
-permeable or pore-dead GluA2-containing AMPARs altered Ca
2+
 
permeability of AMPARs in OPCs, and resulted in the increased proliferation and reduced 
differentiation of OPCs. Expression of GluA2 carboxyl-terminus, which is expected to affect  the 
interaction between GluA2 subunit and AMPARs-binding-proteins and to perturb the trafficking 
of GluA2-containing AMPARs, did not change the Ca
2+
 permeability of AMPARs but 
suppressed the differentiation of OPCs into OLs. The results of my study suggest that properties 
of AMPARs-mediated signaling between neurons and OPCs in the mouse corpus callosum are 
important for regulation of differentiation and proliferation of OPCs. 
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1. Introduction. 
1.1. Oligodendrocytes (OLs) in the central nervous system (CNS). 
OLs were discovered by Pío del Río Hortega [1] and are considered as one type of glial cells in 
CNS. OLs produce large amount of membrane called myelin, which contains high proportion of 
lipids (70-80% dry mass) and small proportion of proteins (15-30% dry mass) [2]. Myelin wraps 
the axons multiple times, and these wraps are called internodes. The neighboring internodes on 
the same axon are separated by the nodes of Ranvier (Fig. 1-1). Myelin sheath acts as insulation. 
This insulation can reduce the attenuation of electrical signal due to its high electrical resistance 
and low electrical capacitance [3]. Therefore, myelination increases the conduction velocity of 
action potential propagating along the myelinated axon.  
 
 
Figure 1-1. Myelination from OLs in CNS. 
(Left) Myelin enwraps axon into several segments. (Right) Cross-section of myelinated axon. IMA: inner 
mesaxons; OMA: outer mesaxons. From [4], modified.  
 
1.2. Development and molecular markers of the oligodendrocyte lineage cells. 
OLs are generated from the oligodendrocyte precursor cells (OPCs), also called NG2-cells and 
polydendrocytes. During development of the oligodendrocyte lineage, OPCs first differentiate 
into  pre-myelinating OLs, which then further mature into OLs (Fig. 1-2). In brain slices, cells at 
each of these three developmental stages can be distinguished using different 
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immunohistochemical markers. OPCs are usually distinguished using labelling for neuron-glial 
antigen 2 (NG2, a product of chondroitin sulphate proteoglycan 4, CSPG4 gene) and α-receptor 
for platelet-derived growth factor (PDGFR α) [5] (Fig. 1-2). Of note, in the brain the expression 
of NG2 is also found in pericytes, which are cellular components of bold vessels [6]. However, 
pericytes are morphologically different from OPCs: they are surrounded by basement membrane 
and extend their processes along and around the microvasculature [7]. With this typical 
morphological feature of NG2-positive pericytes, it is easily distinguished from OPCs which 
have complex morphology. 
In rodents, differentiation of OPCs into pre-myelinating and subsequently into myelinating OLs 
starts from the early postnatal stage, reaches its peak during the second postnatal week (P7-P14), 
and continues till adulthood, in both gray and white matter areas of the brain [8-14] although the 
differentiation rate from OPCs to OLs declines with age [8, 14]. When OPCs start undergoing 
differentiation into pre-myelinating OLs, i.e. the intermediate stage in the lineage cells, NG2 and 
PDGFR α start getting downregulated, and the expression of these markers gets lost when the 
cells become OLs. At the same time, during the process of differentiation, other markers such as 
proteolipid protein (PLP)/DM20, immature OL antigen O4, galactocerebroside O1, and CC1 
(adenomatous polyposis coli, CC1 clone) appear in the pre-myelinating OLs and OLs [15] (Fig. 
1-2). In the final stage of OLs maturation, myelinating OLs express myelin basic protein (MBP), 
myelin associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG) [15-
17]. Majority of the myelin proteins are restricted to the myelin sheaths, and therefore, anti-MBP, 
anti-MAG and anti-MOG antibodies are often used to label myelin sheathes in 
immunohistochemical experiments [15]. For quantification of OLs, other antibodies are usually 
used, e.g. anti-APC, which is a protein expressed in the cell body of OL. 
Pre-myelinating OLs represent an intermediate stage between OPC and OLs. One approach to 
distinguish them in brain slices is to perform co-labelling for NG2 and CC1. Both markers are 
co-expressed in pre-myelinating OLs, but the labelling for NG2 is weaker than in OPCs and 
labelling for CC1 is weaker than in OLs [18]. Recently, a new maker for newly forming OLs, 
ecto-nucleotide pyrophosphatases/phosphodiesterases 6 (Enpp6), was discovered [19, 20]. Enpp6 
is mainly found in early developing OLs. Enpp6 start to express in the cell after the maker of 
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OPCs extinguishes and expression of Enpp6 overlaps with the onset of OLs marker [19, 21]. 
Therefore, Enpp6 may be useful for the detection of pre-myelinating OLs.  
 
Figure 1-2. Schematic drawing showing the development of OL lineage. 
The markers in different stages of lineage cells are listed in the rectangles below each stage of cells. From 
[22], modified. 
 
1.3. OPCs possess electrophysiological properties. 
OPCs are considered special within the oligodendrocyte lineage because they combine properties 
of proliferating progenitors, mature glial cells, and neurons. OPCs are widely spread in the white 
and grey matter area of the CNS and constitute 2-9 % of total cells in the adult rodent brain [23]. 
The discovery of OPCs goes back to 1983, when it has been demonstrated that oligodendrocyte-
type-2 astrocyte (O-2A) progenitor cells purified from rat optic nerve were capable of 
differentiating into oligodendrocytes in culture system [24]. O-2A progenitors in culture co-
express NG2 proteoglycan and PDGFR α, and later on it has been found that these markers are 
expressed by OPCs in brain slices [5]. 
Many studies demonstrated that OPCs possess ion channels including voltage-gate K
+
 and Na
+ 
channels [25]. According to the RNA-sequencing transcriptome data, the mRNA level of Kir4.1 is 
high in OPCs [20]. Kir4.1 is an inwardly rectifying K
+
 channel and expressed predominantly in 
glial cells in CNS [26]. Indeed, when the hyperpolarizing voltage steps were recorded from 
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OPCs, inward K
+
 currents were observed [27-29]. The density of inward K
+
 currents in 
subcortical white matter OPCs was lower than in cortical OPCs although the variations of inward 
K
+
 currents density in cortical OPCs was high [28]. The functional role of Kir4.1 in OPCs is 
unknown. Apart from inward K
+
 currents, voltage-gated outward K
+
 currents were also recorded 
in OPCs when depolarizing voltage steps were applied [27, 29-32]. The outward K
+
 currents 
contained two components: sustained K
+
 currents sensitive to tetraethylammonium [25, 29, 30, 
32] and transient K
+
 currents sensitive to 4-aminopyridine [25, 29, 32]. Voltage-gated K
+
 
channels have been suggested to contribute to the regulation of OPCs proliferation [33, 34].   
Similar to neurons, OPCs also express voltage-gated Na
+
 channels [28, 31, 32, 35-37]. 
Furthermore, when depolarizing currents were injected to OPCs during current clamp recording, 
the “immature” spike-like events with small amplitude could be recorded [28, 37]. The study of 
Karadottir et al. [36] revealed that OPCs were heterogeneous with respect to the expression of 
voltage-gated Na
+
 channels. One group of OPCs was devoid of voltage-gated Na
+
 channels; 
another group of OPCs expressed voltage-gated Na
+
 channels and  generated action potentials 
upon depolarizing current injection [36]. Heterogeneity of OPCs with respect to the expression 
of voltage-gated Na
+
 channels was also reported by another group [38]. The authors showed that 
one-third of non-dividing OPCs generated action potential when depolarized the cell [38]. In the 
population of dividing OPCs, the majority of cells (75.9%) generated spike-like events with 
small amplitude, 18.9% of cells  generated true action potentials, and the remaining 5.2% of cells 
did not produce any spikes even depolarized the cell to 0 mV [38].    
Functional role of ion channels in OPCs is still not fully understood. Interestingly, voltage-gated 
ion channels were not detected in mature OLs [31, 37], suggesting that ion channels are likely 
involved in OPCs development and/or survival.  
1.4. Glutamate receptor in OPCs. 
In addition to expression of complex set of voltage-gated ion channels, OPCs also express 
functional glutamate receptors (see below). Two groups of glutamate receptors are known: 
ionotropic and metabotropic. Ionotropic glutamate receptors are the ion channels which are 
directly activated by the glutamate binding to the receptors. Metabotropic glutamate receptors 
are G-protein-coupled receptor which are also activated by glutamate binding but transduce the 
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signals via G-proteins. Ionotropic glutamate receptors encompass three types of receptors named 
by their selective agonist: N-methyl-D-aspartate (NMDA), 3-hydroxy-5-methyl-4-
isoxazolepropionate (AMPA), and kainate receptor. Metabotropic glutamate receptors are 
composed of 8 subtypes and are categorized into 3 groups according to their sequencing 
homology, signaling pathway, and pharmacology [39-41]. 
OPCs express both ionotropic and metabotropic receptors for glutamate, but the ionotropic 
glutamate receptors have been most extensively studied in these cells so far. Ionotropic 
glutamate receptors have been discovered in OPCs in 1990 using whole-cell patch-clamp 
recordings combined with pressure-application of glutamate onto O-2A progenitors acutely 
isolated from P7 rat optic nerve [42]. In these experiments inward currents were recorded in O-
2A cells (clamped at -80 mV) upon application of 200 µM glutamate (Fig. 1-3 a). Glutamate-
induced inward currents were blocked by 20 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), 
a competitive AMPA/kainate receptor antagonist (Fig. 1-3 a). Furthermore, inward currents 
could also be activated in O-2A cells upon application of 100 µM kainate (agonist for kainate 
receptor) or 100 µM quisqualate (a potent AMPARs agonist) (Fig. 1-3 b, c). At positive holding 
potentials of 20, 40, and 60 mV, application of 100 µM glutamate resulted in outward currents in 
O-2A cells (Fig. 1-3 b, c) and the reversal potential of the current was close to zero mV. These 
data suggested that O-2A progenitors express functional AMPA/kainate receptors [42].   
In the follow-up studies, functional glutamate receptors were found in OPCs (at that time called 
“complex glial cells”) from mouse hippocampal slices [43]. In these experiments, application of 
1 mM glutamate or 1mM kainate to the bath activated inward currents in “complex glial 
cells”clamped at -70 mV [43]. However, application of 5 mM NMDA via the bath failed to elicit 
the response [43]. In another study, it has been shown that glial precursor cells, presumably 
OPCs, in the rat corpus callosum also express AMPA-type glutamate receptors [44]. Co-
application of 30 µM AMPA and 100 µM cyclothiazide (CTZ), a blocker for AMPARs 
desensitization [45, 46], resulted in the enhancement of AMPA-induced currents in these cells 
[44]. Taken together, these findings from different research groups showed that functional 
AMPARs are expressed in OPCs in various brain regions and can be activated by their agonists. 
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Figure 1-3. Activation of glutamate receptors in O-2A progenitors.  
(a) Acutely isolated O-2A progenitors are whole-cell voltage-clamped at -80 mV and inward currents are 
elicited by glutamate puff. (b and c) Currents responses are elicited by kainite and quisqualate puff from -
80 mV to +60 mV in 20 mV increments. (d and e) Elicited peak currents in (b) and (c) are plotted to the 
corresponding voltage. From [42], modified.  
 
1.5. Properties and subunit composition of AMPARs in OPCs. 
In neurons, AMPARs are tetramers and composed of four subunits: GluA1, GluA2, GluA3, and 
GluA4 (also called GluR1-4 or GluRA-D) [47]. Each of the subunit contains an extracellular N-
terminus, an intracellular C-terminus, and four transmembrane domains (Fig. 1-4 a). The 
majority of AMPARs is hetero-tetramers and is assembled from a combination of GluA1/GluA2 
or GluA2/GluA3 subunits [48, 49]. The RNA for GluA2 subunit of AMPARs can be edited at 
the Q/R site resulting in substitution of glutamine (Q) with arginine (R) in the transmembrane 
domain II of the GluA2 subunit (Fig. 1-4 a). GluA2 subunit determines many important 
properties of AMPARs including kinetic of the channels, single-channel conductance, and Ca
2+
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permeability [50]. Edited GluA2 subunit forms heteromers with other subunits of AMPARs, 
these receptors are impermeable to Ca
2+
 (Fig. 1-4 b); while AMPARs containing un-edited/no 
GluA2 subunit are permeable to Ca
2+
 and Zn
2+ 
[51-54].  
GluA2-lacking AMPARs or AMPARs containing unedited GluA2 subunit show inwardly 
rectifying current-voltage (I-V) relationship (Fig. 1-5 a). This effect is attributed to the 
intracellular polyamines which block the ionic flow through the channels at positive potentials 
[55-58]. On the contrary, due to the positive charge of arginine residue at the Q/R editing site of 
the GluA2 subunit, AMPARs containing edited GluA2 limit the passage of divalent ions through 
the channels, rendering the receptors Ca
2+
-impermeable. I-V relationship of these receptors 
displays linearity (Fig. 1-5 b). Therefore, recording AMPAR-mediated currents and constructing 
the I-V relationship allow estimating the presence of edited GluA2 subunit within AMPARs in a 
given cell. To compare the changes in the rectification of I-V relationship of AMPARs in the 
cells under different conditions (e.g. different age of animals), the calculation of rectification 
index is widely used. In general, rectification index is calculated: (1) the peak amplitude of 
AMPARs EPSCs at positive holding potential (+40 mV or +50 mV) divided by the peak 
amplitude of AMPARs EPSCs at negative holding potential (from -60 mV to -90 mV); (2) the 
peak amplitude of AMPARs EPSCs at negative holding potential (from -60 mV to -90 mV) 
divided by the peak amplitude of AMPARs EPSCs at positive holding potential (+40 mV or +50 
mV).  
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Figure 1-4. Structure of AMPARs and the property of AMPARs 
(a) Schematic drawing showing a topology of the AMPAR subunit. Purple circle denotes Q607R editing 
in the GluA2 subunit. (b) (Left) AMPARs lacking GluA2 subunit (receptor showing in light yellow 
represent non-GluA2 subunits). (Middle) AMPARs containing GluA2 subunits (light blue) in unedited 
from (Q in red) also permeates to Ca
2+
. (Right) AMPARs containing GluA2 subunits with RNA edited at 
607 to arginine (R in dark blue) are Ca
2+
-impermeable. From [59]. 
 
 
 
Figure 1-5. Ca
2+
 permeability of AMPARs is examined by the I-V relationship. 
(a) GluA2-lacking AMPARs permeate to Ca
2+
 and displays inward rectifying I-V relationship while 
polyamine is present. (b) GluA2-containing AMPARs are Ca
2+ 
permeable and exhibits the linear I-V 
relationship. The heteromeric GluA2 AMPAR channels restrain the ionic flow of Ca
2+
 and Zn
2+
 resulting 
from the positive charge of R at the Q/R RNA editing site. From [60].  
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Up to date, several studies have reported the subunits of AMPARs at the messenger ribonucleic 
acid (mRNA) and protein level in OPCs. Northern  blot, real-time polymerase chain reaction 
(Real-Time PCR), reverse transcription polymerase chain reaction (RT-PCR), RT-PCR 
combining Southern blot, RNA-Sequencing, and in situ hybridization (ISH) provided the 
evidence that mRNA of GluA1-GluA4 are present in the purified O-2A progenitor cells and 
oligodendroglial lineage from mouse or rat, CG-4 progenitor cell line, rat forebrain, or mouse 
subcortical white matter [20, 61-65]. Some reports indicated that GluA2-4 mRNA were present 
in OPCs at the high level [61, 64] but the GluA1 mRNA was low [61, 64, 65], or not detected at 
all [61]. Furthermore, immunolabeling, Western blot, and immunoprecipitation combined with 
Western blot showed that GluA1-GluA4 proteins were present in purified O-2A progenitor cells,  
and in OPCs purified from the developing rodent brain [66-71], mouse cerebellum, and several 
other regions of rat brain [70, 72]. Consistent with the low level of mRNA for GluA1 subunit, 
the GluA1 protein level was also low [69].  
GluA2 subunit of AMPARs is critical subunit because it determines the properties of AMPARs 
as mentioned above (introduction part of 1.5). Currents induced in cultured purified OPCs by fast 
application of 500 µM kainate displayed linear I-V relationship suggesting that edited GluA2 
subunit is present in the tetrameric AMPARs [73]. Currents triggered in purified O-2A 
progenitor cells by pressure ejection of 100 µM kainate or 100 µM quisqualate also showed 
linear I-V relationship (Fig. 1-3 c). These findings are in agreement with the results of RT-PCR 
showing that purified OPCs contain mRNA for edited GluA2 subunit [66]. Taken together, 
GluA1-GluA4 subunits of AMPARs are present in OPCs but likely differ in their expression 
level. 
1.6. OPCs form synaptic connections with neurons and receive glutamatergic synaptic input 
from neurons. 
When AMPARs were first discovered in OPCs, AMPARs-mediated currents were activated by 
the application of AMPARs agonists via the bath or using pressure-induced application systems 
[42, 66, 73]. However, it was still unclear how AMPARs in OPCs are activated in vivo. The first 
discovery illustrating that these receptors are activated by glutamate which is synaptically 
released from was published by Bergels et al. in 2000 [74]. The authors performed whole-cell 
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voltage clamp recordings from NG2-positive OPCs in hippocampal slices and recorded inward 
currents upon afferent excitatory axonal stimulation.  These evoked currents were blocked by 5 
µM 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo [f] quinoxaline (NBQX), a  competitive antagonist 
for AMPA/kainate receptors (Fig. 1-6 a), and by 10 µM (1-(4-Aminophenyl)-4-methyl-7,8-
methylenedioxy-5H-2,3-benzodiazepine hydrochloride (GYKI 52466), a non-competitive 
antagonist of AMPARs. These evoked currents were enhanced by the application of 100 µM 
CTZ, a substance potentiating AMPAR-mediated currents by preventing desensitization of 
AMPARs [45, 46]. The results of these experiments indicated that recorded axon-OPC currents 
were mediated by AMPARs, and therefore these currents were called neuron-glia excitatory 
postsynaptic currents, EPSCs [74]. In addition to evoked EPSCs, AMPARs-mediated miniature 
EPSCs (mEPSCs) could be recorded in hippocampal OPCs, similarly to neurons. These currents 
occur in response to the release of single neurotransmitter-filled vesicles from the presynaptic 
axons and subsequent binding of the neurotransmitter to the postsynaptic receptors in OPCs (Fig. 
1-6 b). Both evoked EPSCs and mEPSCs (Fig. 1-6 c) recorded in hippocampal OPCs had fast 
rise and decay time constant: rise time: 259±15 µs (20-80%) for mEPSCs and 1.21±0.09 ms for 
evoked EPSCs [74]; decay time constant: 985±58 µs (range from 700-1250 µs) for mEPSCs [74], 
as expected for synaptic currents.  
In addition to electrophysiological evidence for synaptic input from neurons to OPCs, data from 
electron microscopy also revealed that OPCs form synapses with neurons [74]. Thus, it has been 
demonstrated that processes of OPCs filled with biocytin are directly opposed to the vesicle-
filled axonal terminals (Fig. 1-7).  
Taken together, electrophysiological and ultrastructural data demonstrated that OPCs in 
hippocampus establish synaptic structures with neurons and receive excitatory glutamatergic 
AMPAR-mediated synaptic input from neurons. 
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Figure 1-6. EPSCs in OPCs are mediated by AMPARs. 
(a) (Left) Paired stimuli evoked inward currents in OPCs. (Right) These currents are blocked by NBQX. 
(b) Bursts of mEPSCs observed in OPCs are elicited by application of neurotoxin pardaxin. (c) Averaged 
time course of mEPSC obtained from OPCs. The averaged rise time is 295±15 µs and decaying constant 
is 983±58 µs. From [74], modified. 
 
 
Figure 1-7. The formation of axon terminals and OPCs.  
(a-b) Two serial sections of images from electron microscope illustrates that the process of OPC labeled 
with biocytin (black) is apposed to the bouton. (b) forming like a synapse (arrow). From [74], modified.  
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Studies published later demonstrated that the formation of neuron-OPC synapses also takes place 
in rodent white matter, i.e. corpus callosum and optic nerve ([75, 76]). First, evoked synaptic 
currents could be recorded in white matter OPCs upon axonal electrical stimulation [75, 76]. The 
kinetics of evoked currents was fast: rise time20-80%: 655±44 µs, and decay time constant τdecay: 
1.9±0.2 ms [75], similar to neuronal EPSCs and neuron-OPC EPSCs in the hippocampus [74]. 
Furthermore, evoked neuron-OPC synaptic currents in white matter were blocked by the 
antagonists of AMPARs indicating that they are mediated by AMPARs. Evoked responses were 
abolished by application of 0.5 µM tetrodotoxin (TTX) which blocks voltage-gated Na
+
 channels 
and abolishes axonal action potentials, suggesting the glutamate release at neuron-OPC synapses 
in white matter is activity-dependent. Second, AMPARs-mediated mEPSCs with rapid kinetics 
(rise time: 330±55 µs; τdecay: 1.1±0.2 ms) could also be recorded in white matter OPCs. Third, 
anatomical synaptic structures have been described between white matter axons and OPC 
processes [75, 76]. Electron microscopic analysis demonstrated that axonal and OPC processes 
membrane are located in a close parallel opposition. Clear vesicles are accumulated in the axon 
close to the axonal membrane [75]. In addition, immunofluorescent and electron microscopic 
evidence showed that type 1 vesicular glutamate transporter (VGLUT1) could be found inside 
white matter axons, close to the axonal membrane opposing the OPC processes [76]. VGLUT1 is 
one of three VGLUTs expressed by glutamatergic neurons [77]; it is responsible for packing 
glutamate into synaptic vesicles in the presynaptic terminals [78]. 
In subsequent studies, glutamatergic synapses between neurons and OPCs were also discovered 
in different regions of the rodent brain, including cerebral cortex, cerebellum, brain stem, and 
ventrobasal thalamus [79-82]. In addition, glutamatergic neuron-OPCs synaptic currents were 
also recorded in human brain [83]. In that study, the authors had access to human hippocampal 
tissue surgically removed from the patients with pharmacoresistant temporal lobe epilepsy. They 
recorded OPCs in the fimbria and induced glutamatergic mEPSCs in OPCs using application of  
100 µM Ruthenium Red which induces vesicular release of glutamate from the presynaptic sites 
[83]. 
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1.7. The changes in the Ca
2+
 permeability of AMPARs in OPCs.  
During development and also in the adult brain many OPCs effectively differentiate into 
oligodendrocytes. At the same time, many OPCs remain un-differentiated. Surprisingly, neuron-
OPC synapses are also observed in mature animals [74, 84] (Fig. 1-8), and glutamatergic 
synaptic currents can be elicited not only in juvenile (P7) and adolescent (P21), but also in the 
adult (P66) animals. In each case, the currents are abolished by 5 µM NBQX application 
indicating that they are mediated by AMPARs [74].   
It has been reported that the subunit composition of synaptic AMPARs in OPCs changes with 
age of the animal [76] and depends on the brain region. For instance, in the corpus callosum of 
young rodents, I-V relationship of axo-glial currents recorded in OPCs displays linearity (Fig. 1-
9 a), suggesting that callosal OPCs express GluA2-containing Ca
2+
-impermeable AMPARs [75, 
76]. In contrast to young animals, I-V relationship of EPSCs in callosal OPCs from adult animals 
(P42-52) shows marked inward rectification (Fig. 1-9 b), indicating that GluA2-lacking Ca
2+
-
permeable AMPARs are expressed in callosal OPCs later in development [76]. 
 
 
Figure 1-8. Synaptic responses are evoked in OPCs at P7, P21, and P66.  
OPC from hippocampal slice is whole-cell voltage-clamped at different age of animal. Evoked EPSCs 
upon axonal stimulation from OPCs are blocked by NBQX. From [74], modified. 
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Figure 1-9. OPCs in adult corpus callosum express GluA2-lacking AMPARs and permeate to Ca
2+
. 
(a) (Left) The traces illustrate the evoked EPSCs recorded in a callosal OPC with an internal solution 
containing spermine at holding potential of -90, -50, -10, and 30 mV. (Right) I-V relationship of evoked 
axon-OPC EPSCs recorded in OPC from P7-8 animals. (b) Same as in (a) but from P42-52 mature 
animals. Note that filled and open circles in the I-V relationship represent the present and absent of 
spermine in the internal solution. From [76]. 
 
In hippocampal OPCs, changes in the Ca
2+
 permeability of synaptic AMPARs during 
development are different from those in callosal OPCs. In the study of Ge et al. [85], the authors 
examined rectification of evoked EPSCs by calculating the rectification index (as mentioned in 
part 1.5). The rectification index in this study was the ratio of the current amplitude recorded at a 
negative potential (e.g. -60 mV) and the current amplitude recorded at a positive potential (e.g. 
+40 mV). In this case, theoretically, if the I-V relationship is linear, the rectification index will 
be close to 1.5, meaning that AMPARs are Ca
2+
-impermeable. If the I-V relationship shows 
inwardly rectification, the rectification index should be larger than 1.5 depending on the currents 
recorded at +40 mV, meaning that they are Ca
2+
-permeable AMPARs. In young animals at P8-
P10, the rectification index was higher than that at P13-15 and P19-21(Fig. 1-10 a). In addition, 
upon application of 1-naphthyl acetyl-spermine (NAS), an analog of Joro spider toxin which is 
specific blocker for Ca
2+
-permeable AMPARs [86], the axon-OPC EPSCs elicited by the 
stimulation of Schaffer collaterals, are inhibited stronger at P7-P10 than P15-P21 (Fig. 1-10 b). 
This indicates that in the early developmental stage, EPSCs in hippocampal OPCs are mediated 
by Ca
2+
-permeable AMPARs, but during aging AMPARs become Ca
2+
 impermeable [85]. Taken 
together, Ca
2+
 permeability of synaptic AMPARs in OPCs gets altered with age but the changes 
in  Ca
2+
 permeability (from Ca
2+
-impermeable to Ca
2+
-permeable and vice versa) of AMPARs 
depends on the brain region. The reasons for these differences remain unclear so far. It is 
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possible that AMPAR-mediated signaling in OPCs in different brain regions have different roles, 
or that Ca
2+
 permeability of synaptic AMPARs depends on the cellular environment, i.e. 
neuronal bodies in the hippocampus vs. only axons in the corpus callosum.  
 
Figure 1-10. The alteration of Ca
2+
-permeability of AMPARs in developmental hippocampal OPCs. 
(a) Averaged rectification index of evoked EPSCs recorded in hippocampal OPCs. Insets illustrate the 
example EPSCs recorded at holding potential of -60 mV (black) and +40 mV (red). Asterisks indicate the 
significant differences as compared to P8-10 group. p < 0.01. (b) Averaged EPSCs are normalized by 
EPSCs in the presence of NAS divided by control EPSCs (before NAS application). Comparison is 
performed between two experimental groups indicating as one asterisk (p < 0.05) or with control group 
indicating as two asterisks (p < 0.001). From [85], modified. 
 
1.8. Synaptic inputs are lost during the differentiation of OLs lineage. 
As indicated above, OPCs constantly differentiate into OLs. Therefore it was important to find 
out what happens to the synaptic inputs between axons and OPCs when OPCs differentiate into 
OLs. In theory, these inputs may disappear or they may persist in all cells of the 
oligodendrocytes lineage. To address this question, Ruthenium Red, a drug which provokes 
vesicular release of neurotransmitters from presynaptic terminals and increases the frequency of 
mEPSCs in hippocampal pyramidal neurons [87] has been tested in the oligodendrocyte lineage 
cells  [31, 65, 76]. Application of 100 µM RR to OPCs in hippocampal slices induced inward 
currents with fast kinetics (rise time: 0.5±0.07 ms; decay time constant: 2.4±0.19 ms), similar to 
mEPSCs (Fig. 1-11 a). On the contrary, inward currents could not be detected in mature 
myelinating OLs recorded under similar conditions (Fig. 1-11 c, d).  In pre-myelinating OLs only 
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very few mEPSCs with similar amplitude and kinetics could be recorded upon Ruthenium Red 
application (Fig. 1-11 b, d), indicating that they receive much less synaptic input than OPCs [31]. 
These data show that axons establish synaptic inputs mediated by AMPARs only with OPCs, but 
not with more mature cells of the OLs lineage.  
The reduction in the frequency of mEPSCs in pre-myelinating OLs, and subsequently in mature 
OLs, reflects the loss of the synaptic signaling upon differentiation of OPCs. A possible reason 
for this can be the decrease in the expression of functional AMPARs. To address this question, 
inward currents triggered by uncaging of 500 µM 4-Methoxy-7-nitroindolinyl-caged-L-
glutamate (MNI- glutamate) were tested in different stages of OLs lineage [37]. Glutamate-
induced currents were detected in OPCs and pre-myelinating OLs, and the induced currents were 
blocked by the antagonists of AMPARs NBQX and GYKI53655 (Fig. 1-12 a,b). However, the 
current amplitude in pre-myelinating OLs was remarkably smaller than in OPCs (Fig. 1-12 d). 
Photolysis of MNI-glutamate also induces detectable inward current in OLs; however, this 
current was not inhibited by antagonists of AMPARs (5 or 50 µM NBQX and 100 µM GYKI 
53655) but was significantly reduced by application of 300 µM DL-threo-β-benzyloxyaspartic 
acid (TBOA), a potent glutamate transporter blocker, indicating that it is contributed largely by 
glutamate transporters (Fig. 1-12 c), although AMPARs expression has been reported in OLs 
[88]. During oligodendrogenesis, the cells become larger [37], therefore to compare the inward 
currents in OPCs, pre-myelinating OLs, and OLs, the amplitude of AMPARs mediated currents 
triggered by glutamate un-caging, were normalized on the membrane capacitance. The density of 
AMPAR-mediated currents in OPCs turned out to be significantly higher than in pre-myelinating 
OLs and OLs (Fig. 1-12 d), suggesting the surface expression of AMPARs gets reduced when 
OPCs commence to differentiate.  
Taken together, these data indicate that AMPAR-mediated synaptic input is lost and the 
expression of functional AMPARs is downregulated during maturation of the OL lineage cells 
[31, 37]. These may imply that synaptic input acts as a modulator for OPCs to undergo 
differentiation. 
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Figure 1-11. Synaptic currents are vanished during the maturation of OL lineage cells. 
(a) Ruthenium Red induces mEPSCs obtained in OPC from the whole-cell voltage clamp recording.  
Calibration: 0.2 s, 2 pA. Inset: The expended trace is from the part of the top trace. Calibration: 20 ms, 5 
pA. The asterisks from both traces indicate the same events. (b) Same as (a) but obtained from pre-
myelinating OL. (c) Same as (a, b) but obtained from pre-myelinating OL. (d) (Top) Summary bar graph 
represents the mean frequencies of mEPSCs recorded from OL lineage cells. (Bottom) Summary graph 
depicts the mean amplitude of mEPSCs recorded from OL lineage cells. From [31], modified. 
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Figure 1-12. Expression of AMPARs is declined in the oligodendrogenesis.  
(a) Glutamate uncaging (black dot) triggers inward current in OPC (Vh=-80 mV). (b) Same as (a) but in 
pre-myelinating OL. (c) Same as (a, b) but in OL. Inset: expanded trace from the top trace showing initial 
response at the shorter time scale. Bar: 20 ms. (d) AMPAR current is normalized by the membrane 
capacitance for OPCs, pre-myelinating OL, and OLs. Red asterisk: OPC vs pre-myelinating OL and OPC 
vs OL, p < 0.001; blue asterisk: pre-myelinating OL vs OL, p < 0.001. From [37], modified. 
 
1.9. Synaptic currents in proliferating OPCs. 
OPCs receive synaptic inputs from neurons in both young and adult animals [74]. At the same 
time, OPCs continue proliferation throughout the life [23]. Do OPCs pass through their synaptic 
connection with neurons to their daughter cells upon cell division? Or do the daughter cells lose 
synaptic inputs during mitosis and establish synaptic connection with neurons de novo after 
completing the cell division? To answer this question, it was tested whether glutamatergic or 
gamma-aminobutyregic (GABAergic) synaptic currents can be recorded in OPCs at different 
stage of the cell cycle. It turned out that during metaphase and telophase of mitosis, mEPSCs 
mediated by AMPARs and GABARs could be recorded in OPCs suggesting that functional 
synaptic connections are preserved during cell division [38, 89]. In addition, immunolabeling 
data showed that punctate glutamic acid decarboxylase 65 (GAD65, localized preferentially in 
GABAergic terminals [90]) staining was observed close to the processes of mitotic OPCs filled 
with a fluorescent dye Lucifer yellow [89]. Taken together, OPCs keep functional synaptic 
connections with neurons during their division, and their daughter cells inherit the glutamatergic 
and GABAergic synaptic inputs from parent OPCs. This inheritance of synapses may help OPCs 
to continue being involved in synaptic signaling with neurons immediately after the cell division, 
and may be a mechanism important for maintaining the OPC populations in the brain. 
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1.10. The role of AMPAR-mediated signaling in OPCs during demyelination and remyelination 
process.  
In the experimental models of demyelination induced by injection of lysolecithin or ethidium 
bromide in the rodents, OPCs are recruited to the demyelination lesion and establish AMPARs 
mediated synaptic connections with axons approximately one week after induction of 
demyelination [91-93]. The number of newly-born OLs increases in the lesion 10-14 days after 
demyelination [91, 93]. Interestingly, infusing 250 µM NBQX (antagonist of AMPARs) into the 
demyelinating lesion via an intrancerebral cannula decreases remyelination [92]. This evidence 
suggests that synaptic connection between neurons and OPCs via AMPARs may initiate 
activation of intracellular cascades in OPCs which are required for differentiation of OPCs into 
OLs and/or for remyelination.  
1.11. Neuronal activity affects differentiation and proliferation of OL lineage cells, as well as 
myelination. 
It has been shown in different brain regions and in the optic nerve in vivo, ex vivo, or in vitro that 
neuronal activity affects differentiation and/or proliferation of OPCs, or myelination [18, 82, 94-
98]. Published research on this topic can be grouped in two parts: studies focusing on the effects 
of inhibition of neuronal activity on OPCs development and studies focusing on the effects of 
enhanced neuronal activity on OPCs development.  
In general, the results of the studies reporting effects of reduced neuronal activity on 
proliferation and differentiation of OPCs are so far contradictory. Elimination of electrical 
activity from  the axons of retinal ganglion cells by transection of the rat optic nerve, resulted in 
reduction of proliferative capacity of OPCs [96]. However, an increase in proliferation of OPCs 
upon inhibition of neuronal activity has also been reported [82, 95]. Sensory deprivation by 
removing and cauterizing the whisker at birth of a mouse resulted in reduced thalamocortical 
glutamatergic (mainly AMPARs-mediated) synaptic inputs to OPCs, but increased proliferation 
of OPCs in the barrel cortex during early mouse development [82]. In addition, another study 
using similar approach for sensory deprivation by whisker clipping found increase in the 
apoptosis of dividing OPCs in somatosensory barrel cortex [98]. Blockade of neuronal activity 
by 1 mM TTX application in cerebellar slice culture increased proliferation of OPCs and the 
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generation of OL [95]. Moreover, blockade of neuronal activity has also been reported to alter 
the morphology of OPCs, e.g. induced shortening the processes length and processes branching 
points [95]. In addition to the effects of reduced/diminished neuronal activity on differentiation 
and/or proliferation of OPCs, blockade of neuronal activity has also been shown to affect 
myelination. Thus, application 1 mM TTX in cerebellar slice culture suppressed myelination [95]. 
In co-culture of neurons and OPCs prepared from cerebral hemispheres, 1 µM TTX treatment 
decreased the number of myelinated segments [97]. This study further demonstrated that 
intravitreal injection of 100 µM TTX into P4 mouse optic nerve in vivo decreased the total 
number of myelinating OLs. Interestingly, similar effects was not observed in P5 mouse optic 
nerve, suggesting that electrical activity in axons affects only the onset of myelination [97]. 
Augmentation of neuronal activity also has an effect on the OL lineage cells. Enhancement of 
neuronal activity in co-culture of neurons and OPCs by treatment with highly selective Na
+
 
channel activator alpha-ScTX increased the number of myelinated segments without increasing 
the number of OLs [97]. Furthermore, increase of neuronal activity via optogenetic stimulation 
of the premotor cortex in awake and behaving mice in vivo led to increase in proliferative 
capacity of OL lineage cells in several brain regions including premotor cortex and corpus 
callosum [94]. Optogenetic stimulation also promoted oligodendrogenesis [94] and resulted in 
thicker myelin which was reflected in the reduction of g-ratio, which is the ratio between the 
diameter of an axon and  the diameter of this axon together with myelin sheath [94]. Remarkably, 
it appeared that differentiation and proliferation of OPCs is not only affected by neuronal activity 
itself but also depends on the patterns of activity. Thus, a recent study showed that stimulation of 
callosal axons at 5 Hz but not at 25 or 300 Hz in freely moving mice in vivo promoted 
differentiation of OPCs into OLs [18]. On the other hand, stimulation at 25 and 300 Hz but not at 
5 Hz enhanced proliferation of OPCs. , All frequencies tested in that study (5, 25, and 300 Hz) 
promoted oligodendrogenesis of newly born OPCs into OLs [18]. 
Taken together, neuronal activity, indeed, affects the differentiation and proliferation of OPCs 
and the further myelination of OLs in the different systems. However, the mechanisms mediating 
the effects of neuronal activity on the OLs lineage are still ambiguous. Further studies addressing 
this question are necessary. 
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1.12. AMPARs in OPCs affect proliferation and differentiation of OPCs, as well as myelination. 
Glutamatergic AMPAR-mediated neuron-OPC signaling may be one of the mechanisms 
mediating the effects of neuronal activity on the behavior of OPCs. AMPARs have been shown 
to participate in regulation of the behavior of OPCs in different systems. Application of 200 µM 
AMPA, an agonist of AMPAR, in rat cerebellar tissue culture decreased the percentage of 
proliferating OPCs (NG2
+
 cells), and also decreased the level of 2’, 3’-cyclicnucleotide 3’-
phosphodiesterase (CNP) mRNA. CNP is expressed selectively in OLs [99] and represents a 
marker of maturation of OLs. These findings indicated that activation of AMPARs inhibited 
proliferation of OPCs and suppressed OLs maturation [33]. Application of 30 µM 6,7-
dinitroquinoxaline-2,3-dione (DNQX), an antagonist of AMPAR, reversed this effect by 
increasing the number of proliferating OPCs (NG2
+
 cells) and the level of CNP mRNA [33]. 
Similar results were obtained in a study from a different group who demonstrated that blockade 
of AMPAR function by GYKI (9.74 mM) increased proliferation of oligodendrocyte lineage 
cells, increased generation of OLs, and suppressed myelination in cerebellar slice culture [95]. 
Furthermore, blockade of AMPARs reduced the length and the number of branching points of 
OPCs processes [95]. Although these findings are valuable, the environment in the slice culture 
is more simplified than in vivo, and the blockade of AMPARs in culture systems is not specific 
to OPCs but is also expected to affect neurons. Therefore, the observed effects on OPCs may 
(partially) be mediated through other surrounding cells which express AMPARs and probably 
release several factors onto OPCs. Thus, it was important to study role of AMPARs for OPCs 
development and function in vivo, and this question was addressed in a recent study which aimed 
to understand the effects of AMPAR-mediated signaling in OPCs and OL lineage cells in general 
[65].  As GluA1 subunit is low in callosal OPCs, in order to study AMPAR function the authors 
ablated two (GluA2/3) or three (GluA2/3/4) subunits of AMPARs in OPCs from the onset of 
mouse development [65]. In both cases, AMPARs-mediated synaptic input to OPCs was reduced 
or abolished [65]. In both double and triple knockouts, the proliferation of OPCs was not altered 
but reduced number of OLs was observed [65]. In triple-knockouts, reduction in the number of 
OLs continued into adulthood [65]. The authors further showed that reduction in the number of 
OLs was due to the increased death of OL lineage cells [65]. Interestingly, although the number 
of OLs was affected in double and triple knockouts, the average length, number and thickness of 
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myelin internodes remained normal [65]. Together, these findings suggest that AMPARs-
mediated signaling between callosal axons and OPCs promotes survival of the OL lineage cells 
[65]. Regulation of differentiation and proliferation in OPCs is complicated and may involve 
several pathways. AMPARs-mediated signaling may be one of these mechanisms. Ablation of 
AMPARs in OPCs from the onset of development may prompt compensatory mechanisms which 
come from others pathways. This compensation may re-adjust the regulation and balance 
between differentiation and proliferation in OPCs. 
Taken together, functional role of AMPAR-mediated synaptic signaling between axons and 
OPCs is still ambiguous. In order to investigate the effects of this signaling on differentiation and 
proliferation of OPCs, the present study modified the GluA2 subunit of AMPARs in OPCs in 
vivo. I have chosen to modify the GluA2 subunit for two reasons. First, GluA2 subunit governs 
the Ca
2+
 permeability of AMPARs, and Ca
2+
 is a well-known secondary messenger which is 
involved in several pathways in the cells. Second, Ca
2+ 
permeability of AMPARs in OPCs 
changes during animal age, and this correlates with alterations in the rate of proliferation and 
differentiation of OPCs. In order to modify the GluA2 subunit of AMPARs in callosal OPCs in 
vivo, I used the retroviral approached and carried out the modifications during the second 
postnatal week when synaptic connections between neuron and OPCs are established.  
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2. Hypothesis, objectives, and experimental strategy.  
2.1. Hypothesis. 
The major hypothesis of my study is that axon-OPC signaling through AMPARs regulates 
differentiation and proliferation of OPCs in vivo. 
2.2. Objectives: 
To test my hypothesis, I followed three objectives: 
 (1) Establish an approach to modify AMPARs in callosal OPCs in vivo;  
 (2) Investigate changes in synaptic AMPAR-mediated currents in OPCs; 
 (3) Investigate how modifications of AMPAR properties in callosal OPCs affect differentiation  
      and proliferation of OPCs. 
2.3. Experimental strategy. 
In order to modify the properties of AMPARs in callosal OPCs, I carried out three modifications 
of the GluA2 subunit (Fig. 2-1).  
(1) The first modification, GluA2(R583Q)-GFP, was aimed at increasing the Ca
2+
 permeability 
of AMPARs by a point mutation, i.e. replacing Arg(R)583 with Gln(Q) [100]; I called this 
modification “Ca2+-permeable”.  
(2) The second modification, GluA2(R583E)-GFP, was aimed at reducing the conductance of the 
channel pore by a point mutation, i.e. replacing the Arg(R)583 with Glu(E) in the GluA2 channel 
pore [101]; I called this modification “pore-dead”.  
(3) The third modification, expression of cytoplasmic carboxyl-terminal (GluA2(813-862)) of 
GluA2, was aimed at perturbing the trafficking of GluA2 subunit by affecting the interaction 
between the GluA2 and the AMPAR-binding proteins [102]; I called this modification “C-tail”.  
Each construct was tagged with the green fluorescent protein (GFP) to label cells expressing the 
modified AMPARs. 
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Figure 2-1. Schematic drawing of GluA2 subunit of AMPARs and the constructs used in the study. 
(a) Schematic drawing of the GluA2 subunit of AMPARs. Magenta dot indicates the Q/R editing site of 
the GluA2 subunit. Q: glutamine, R: arginine, TM: transmembrane domain, N: N-terminus, C: C-
terminus. (b) Scheme illustrating the mutated and truncated GluA2 subunits expressed by the viral vector 
shown in Figure 4a. The number 583 indicates the amino acid site of the point mutation. N: N-terminus, C: 
C-terminus. 
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3. Materials and Methods. 
3.1. Animals. 
NG2DsRedBAC transgenic mice [76] and C57BL/6N mice of both sexes were used in all 
experiments. Breeding pairs of NG2DsRedBAC transgenic mice were originally obtained from 
The Jackson Laboratory (stock 008241) and C57BL/6N mice were originally obtained from 
Charles River. Mice were bred in house and kept in 12-12 hours of light-dark cycle; food and 
water were available ad libitum. All experiments were performed in accordance with current 
European Union guidelines and approved by the local government authorities for Animal Care 
and Use (Regierungspraesidium Tuebingen, State of Baden-Wuerttemberg, Germany). 
3.2. Molecular biology. 
pCI-EGFPGluA2(R583Q) was a gift from Roberto Malinow (University of California, USA). 
pEGFPC1-GluA2(813-862) was a gift from Ingrid Ehrlich (University of Tübingen, Germany). 
The plasmids for viral production (pRetroCAG-GFP, pCMV-gp and pCMV-vsv-g) were the gifts 
from Fred Gage (The Salk Institute, USA).  
3.2.1. Mutagenesis. 
The point mutation of GluA2(R583Q) to GluA2(R583E) was introduced using the Quick Change 
II XL Site-Directed mutagenesis kit (Stratagene). The primers for the point mutation were (5’ to 
3’): fwd: CTTGGGTGCCTTTATGGAGCAGGGATGCGATATTTC and rev: 
GAAATATCGCAT CCCTGCTCCATAAAGGCACCCAAG. For all procedures I followed the 
instruction manual provided by Stratagene. Briefly, the sample reaction included 5 µl of 10x 
reaction buffer, 10 ng of double-stranded DNA (dsDNA) template, 125 ng of forward primer, 
125 ng of reverse primer, 1 µl of deoxynucleotide triphosphates (dNTP) mix, 3 µl QuikSolution 
and distilled H2O (ddH2O) to a final volume of 50 µl. Then 1 µl of PfuUltra high-fidelity (HF) 
DNA polymerase (2.5 U/µl) was added into mixture. 18 cycles were performed (95°C, 1 minute; 
denaturation at 95°C, 50 seconds; annealing at 60°C, 50 seconds; extension at 68°C, 8.5 minutes; 
final elongation at 68°C, 7 min). After cycling, 1 µl of the Dpn I restriction enzyme (10 U/µl) 
was added directly to each amplification reaction and incubated at 37°C for 1 hour in order to 
digest the parental supercoiled dsDNA. DNA was treated with Dpn I and was transformed into 
26 
 
XL10-Gold ultracompetent cells. After transformation, XL10-Gold ultracompetent cells was 
plated onto lysogeny broth (LB: 10 g of tryptone, 5 g of yeast extract, 10 g of NaCl, 15 g of agar 
and ddH2O up to 1 liter) agar plates containing ampicillin (100 µg/ml) and incubated at 37°C 
overnight. The liquid bacteria culture was inoculated in the LB medium by picking single colony. 
Miniprep and Maxiprep were performed using QIAprep Spin Miniprep Kit (Qiagen) and 
QIAfilter Plasmid Maxi Kit (Qiagen) respectively. The mutant plasmid was checked by the 
restriction enzymes HindIII (New England Biolabs) and NdeI (New England Biolabs). The 
digested plasmid was run on 0.7% agarose gel. The expected fragments were 8.2 kbp for HindIII 
digestion, and 3 kbp, 2.7 kbp, and 2.4 kbp for NdeI digestion. The 1 kbp-DNA marker (Roth) 
was used. The gel was visualized by BIOVISION-3020-WL/LC/20M system (Vilber Lourmat) 
and the software VisioCapt 15.06 (Vilber Lourmat). 
3.2.2. Subcloning. 
The procedure of cloning is shown on Figure 3-1. In general, the restriction enzymes (AgeI and 
PmeI) for the subcloning were added to the flank of insert by polymerase chain reaction (PCR). 
At the same time, the vector was digested with the same restriction enzymes which were used for 
the insert. Both insert and vector were isolated by gel purification and the insert was ligated into 
the vector. The newly generated retroviral vector was transformed into Stabl3 competent cells 
(Invitrogen). Finally, the single bacterial colonies were picked and purified and the DNA was 
checked by several digestions with restriction enzymes. All plasmids were sequenced to ensure 
the accuracy. 
To construct pRetroCAG-EGFPGluA2(R583Q), pRetroCAG-EGFPGluA2(R583E) and 
pRetroCAG-EGFPGluA2Ctail, I inserted EGFPGluA2(R583Q), EGFPGluA2(R583E) and 
EGFPGluA2(813-862) by PCR amplication. PCR primers included PmeI and AgeI restriction 
site for insertion into pRetroCAG-GFP. The primers are listed in Table 3-1. 
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Figure 3-1. Schematic diagram of the subcloning procedure.   
The insets were digested with the respective digestion enzymes from original plasmids. The digested 
insets were subcloned into retroviral backbone. From [103], modified. 
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Construct Primers (5’ to 3’) Insert size 
EGFPGluA2(R583Q) 
and 
EGFPGluA2(R583E) 
Forward:  
TTACCGGTACGACTCACTATAGGCTAGAACTAG 
          AgeI 
3.855 kbp 
Reverse:  
TGTTTAAACCCAAGGCCTGCATGCACTGCTTTG 
        PmeI 
EGFPGluA2(813-862) 
Forward:  
TAGCGCTACCGGTCGCCACCATGGTG 
                       AgeI 
975 bp 
Reverse:  
TGGTTTAAACACCTCTACAAATGTGGTATGGCTG       
            PmeI                                     
Table 1. The primers used for cloning the inserts into retroviral backbone.   
The nucleic acid sequences underlined with red line indicate the sequences for PmeI or AgeI restriction 
enzyme.    
 
The master mix included 50 ng template, 10 mM dNTP, 10 µM forward primer, 10 µM reverse 
primer, 1 units Phusion DNA Polymerase (New England Biolabs) and 1x Phusion HF buffer. 
The PCR cycle is listed below:  
 98°C 30 sec – Initial Denaturation 
 3-step  cycling 
1. 98°C 10 sec 
2. 70 °C 30 sec  
3. 72°C 2 min for EGFPGluA2(R583Q) and EGFPGluA2(R583E); 30 sec for    
    EGFPGluA2(813-862) 
           30 cycles for 1-3 steps 
 72°C 10 min – Final Extension 
 4°C forever 
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After PCR cycling, PCR product was loaded onto 0.7 or 1% agarose gel. DNA was extracted 
from the gel by QIAquick Gel Extraction Kit (QIAGEN).   
10 µg of vector and purified insert were digested by AgeI and PmeI at 37°C for 3 hours. 
Digested insert was purified by the QIAquick PCR Purification Kit (QIAGEN). The digested 
vector was heat inactivated at 65°C for 20 minutes. Subsequently, 1 µl of calf intestinal alkaline 
phosphatase (CIP; New England Biolabs) was added and the mixture was incubated at 37°C for 
1 hour to avoid the self-ligation. Digested vector was run onto 0.5% agarose gel and extracted 
DNA from the gel. The expected size of digested vector was 6.8 kbp.  
1:3 and 1:5 of ligation ratio were used as a starting point. 300 ng of vector was applied to each 
ligation. The amount of insert was calculated by the formula shown below:  
                                          Y ng of vector * kb size of insert                                       insert 
              X ng of insert =  ----------------------------------------------  *  molar ratio of  -------- 
                                                       kb size of vector                                                    vector    
The mixture of ligation reaction included vector, insert, 10 µl of 2X Quick Ligation Reaction 
Buffer and 1 µl of Quick T4 DNA Ligase (Quick Ligation Kit, New England Biolabs). The 
reaction was incubated at room temperature for 10 minutes. The ligation mixture was 
transformed into Stbl3 competent cell and cultured single colony in the LB medium. Plasmid 
was purified as described above. Plasmids were checked by the restriction enzymes and run onto 
0.7% agarose gel. The restriction enzymes and fragment size are listed in Table 2. 
To check whether GFP, used as a fusion protein, was functionally expressed, HEK 293 cells 
were transfected with each newly generated retroviral plasmid (Table 2) using lipofection 2000 
(Invitrogen) according to the manufacturer’s protocol. 48 hours after the transfection, cells were 
fixed on the glass coverslips with 4% paraformaldehyde at room temperature for 20 minutes and 
washed with 10 mM phosphate-saline buffer (PBS). For counterstaining of the nuclei I used 
Diamidino-2-phenylindole dihydrochloride (DAPI, 0.2 µg, Sigma).  
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Plasmid Restrict enzyme Fragment size Purpose 
pRetroCAG-
EGFPGluA2(R583Q) and 
pRetroCAG-
EGFPGluA2(R583E) 
PmeI 10.6 kbp Linearised 
AgeI/PmeI 6.8 and 3.841 kbp Backbone and Insert 
PvuII/ClaI 8.278 and 2.35 kbp Orientation 
pRetroCAG-
EGFPGluA2(813-862) 
PmeI 7.7 kbp Linearised 
AgeI/PmeI 6.8 and 0.9 kbp Backbone and Insert 
XhoI 6.935 and 0.779 kbp Orientation 
Table 2. Overview of the diagnostic restriction digestion. 
 
3.3. Retrovirus production. 
For retroviral production, I used the procedure described previously [104], with few 
modifications. HEK 293T/17 (ACTT) cells were used for virus preparation. HEK 293T/17 cells 
were cultured with complete growth medium (Dulbecco’s Modified Eagle’s Medium containing 
4500 mg glucose/L, 110 mg sodium pyruvate/L and L-glutamate (PAA and Sigma), 10% fetal 
bovine serum (Life technologies), and 1% Penicillin/Streptomycin (PAA)). 0.25% Trypsin-
EDTA (Sigma) was used to detach the cells during subculturing. All procedures are described in 
details shown below:  
Day1: Plate 5X10
6
 cells per 10 mm plate for a total of 6 plates.  
Day2: Transfection: transfect three plasmids into cells with lipofectamine 2000  
          (1) Prepare 4 tubes with 2.4 ml OptiMEM (Invitrogen) 
          (2) Two tubes: add 45 µg plasmid DNA mixture  
 22.5 µg pRetroCAG - with GFP, GluA2(R583Q) or GluA2Ctail 
 15 µl pCMV-gp 
 7.5 µg pCMV-vsv-g 
          (3) Two tubes: add 150 µl lipofectamine 2000  
          (4) Mix one tube of plasmid DNA with one tube of lipofectamine 2000 
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          (5) Incubate at room temperature for 20-30 minutes 
          (6) Transfer 1.6 ml of the DNA/lipofectamine solution onto each plate of   
                HEK293T/17 cells containing 10 ml of OptiMEM 
          (7) Incubate for 9-16 hours at 37°C, 5% CO2  
          (8) Replace supernatant with 10 ml complete growth medium 
Day4: Concentrate virus – 48 hours after transfection 
          (1) Collect the supernatant in 50 ml Falcon tube and add 10 ml complete growth   
               medium into each plate  
          (2) Centrifuge at 1000g for 3 minutes in order to remove cell debris 
          (3) Pre-wet the 0.45 µm filter (Merck) with complete growth medium 
          (4) Filter the supernatant through pre-wet 0.45 µm filter in two 36 ml          
               ultracentrifuge tubes (Thermo Scientific) 
          (5) Add Dulbecco's Phosphate-Buffered Saline (PBS; PAA and Sigma) till ~ 0.5 cm   
               from the top of the tubes 
          (6) Centrifuge at 65,000g and 4°C with the rotor AH-629 (Thermo Scientific) for 2   
               hours   
          (7) Remove the supernatant  
          (8) Add around 400 µl of PBS in the tubes 
          (9) Cove the tubes with parafilm and store at 4°C for overnight 
Day5: Concentrate virus – 72 hours after transfection 
          (1) Collect the supernatant in 50 ml Falcon tube 
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          (2) Centrifuge at 1000g for 3 minutes in order to remove cell debris 
          (3) Pre-wet the 0.45 µm filter with complete growth medium 
          (4) Filter the supernatant through pre-wet 0.45 µm filter in two 36 ml          
               ultracentrifuge tubes from Day4 
          (5) Add PBS till ~ 0.5 cm from the top of the tubes 
          (6) Centrifuge at 65,000g and 4°C with the rotor AH-629 for 2   
               hours   
          (7) Remove the supernatant  
          (8) Resuspend virus with 0.7 ml PBS for each tube (total is 1.4 ml) 
          (9) Pipette up and down for 20-30 times (avoid any air bubbles during pipetting) 
          (10) Transfer 1.4 ml into one 4 ml ultracentrifuge tubes (Thermo Scientific) 
          (11) Wash tubes with 0.7 ml PBS and transfer to 4 ml tube mentioned in step (10) 
          (12) Fill more PBS till 0.5 cm from the top of the tube 
          (13) Centrifuge at 65,000g using the rotor TH-660, 4°C for 2 hours   
          (14) Remove the supernatant as much as possible 
          (15) Add 40 µl PBS in to the tube and resuspend the final pellet by vortexing for   
                 30 seconds and then by pipetting 
          (16) Transfer 40 µl virus solution to 0.5 ml tube 
          (17) Wash 4 ml tube once with 5 µl PBS (optional) 
          (18) Put 0.5 ml tube on ice and shake for 1-3 hours 
          (19) Spin o.5 ml tube briefly, aliquot and store at -80°C  
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To estimate the viral titers, the procedure was followed:  
   (1)   Dilute 2 µl of the viral stock solution into 100 µl medium (1:50) and mix well 
(2)   Make a series of 10 + 90 µl dilutions:  
1. Prepare 6 eppendorf tubes with 90 µl medium in each  
           2.    Add 10 µl of the initial dilution from step (1) into the first tube and mix well   
                    (1:500) 
            3.   Add 10 µl of the 1:500 dilution into the second tube and mix well (1:5000) 
            4.   Proceed down to 1: 5 x 10
7 
(3)   Adjust HEK293T/17 cells to 1 x 10
6
 cells/ml  
(4)   Add 100 µl of the cell suspension to each viral dilution and mix well.  
        The viral dilution factor is now 1:1000, 1:10000 down to 1: 10
8
.  
        The cell density in all samples is 5 x 10
5
/ml 
(5)   Add 250 µl medium per well (6 wells in total) in a 48-well plate 
(6)   Plate each dilution directly into the wells (100 µl each), starting with 1: 10
4
 
        Mix each sample well before plating 
(7)   Grow cells for 3 days 
(8)   In order to have better GFP visualization from the groups of retrovirus carrying point  
       mutation of GluA2 subunit, the GFP staining was performed:   fix with 4% PFA at  
       room temperature for 20 minutes, apply chicken anti-GFP antibody at 4°C overnight  
       followed by applying anti-chicken FITC secondary antibody  
   (9)   Count fluorescent clones per sample; count samples containing > 20, but < 200 clones 
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   (10) Calculate titer (unit is presented as per ml) as the formula shown below:  
           N of clones x 2 (1/2 of 200 µl cell suspension) x 10
x
 (dilution factor which the number of     
           clones counted) x 500 (initial dilution)  
The viral titers were tested with HEK293T/17 cell line and were 10
8
-10
9
/ml. 
3.4. Experimental groups of animals. 
In the majority of experiments the following 4 groups of animals were used: (1) Animals injected 
with retrovirus-GFP (called “GFP”); (2) Animals injected with retrovirus-GluA2(R583Q)-GPF 
(called “Ca2+-permeable”); (3) Animals injected with retrovirus-GluA2(R583E)-GFP (called 
“pore-dead”); and (4) Animals injected with retrovirus-GluA2(813-862)-GFP (called “C-tail”). 
In some expetriments (see text) a fifth group of mice was used which contained intact animals, 
which were not injected with retrovirus (non-injected). The number of animals (n) used in each 
experiment is indicated in the corresponding figure legends. 
3.5. Retrovirus injection. 
10-12 days-old NG2DsRedBAC transgenic mice were anesthetized with a mixture of isoflurane 
and oxygen (1-3 % v/v) and fixed in the stereotaxic frame (Stoelting, USA). The depth of the 
anaesthesia was monitored by testing the reaction of the mouse to a toe pinch. For analgesia 
metacam (1 mg/kg bodyweight, Boehringer Ingelheim) was injected subcutaneously before the 
surgery. The skin above the skull was disinfected, a small cut was made, and xylocaine (2%, 
Astra Zeneca) was applied locally. Bilateral injections of the virus into the corpus callosum were 
performed using the following coordinates (in mm from Bregma): anteroposterior 0.23, 
mediolateral ±0.23-0.25, dorsoventral 1.77. For each injection I used a glass micropipette 
containing ~2.5 μl viral stock solution. The micropipette was connected to the fast pressure 
application system (PDES-01D-4, NPI Electronic, Germany), and the following parameters were 
used for injection: pressure 16-20 psi, application duration 60-90 ms. Subsequently, the wound 
was sutured with silk (Ethicon, USA). After the surgery, mice recovered rapidly from anesthesia 
and were returned to their home cages with parents. 
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For electrophysiological experiments I used DsRed
+
 mice; for immunohistochemistry and cell 
counting I used DsRed
- 
littermates in order to have red fluorescent channel available for 
antibodies labeling. 
3.6. In vivo EdU treatment.  
To study cell proliferation, mice were administrated with 5-ethynyl-2’-deoxyuridine (EdU, 
Thermo Fisher) [105] intraperitoneally at a dose of 25 mg/ kg body weight. EdU was applied 
three times, i.e. on the third, fourth, and fifth day after the viral injection at an interval of 24 
hours. 
3.7. Slice preparation for electrophysiology. 
Three to five days after the viral injection mice were anesthetized with a mixture of isoflurane 
and oxygen (3% v/v) and decapitated. The brain was dissected in the ice-cold N-methyl-D-
glucamine (NMDG)-based solution containing (in mM): 135 NMDG, 1 KCl, 1.2 KH2PO4, 20 
choline bicarbonate, 10 glucose, 1.5 MgCl2, and 0.5 CaCl2 (pH 7.4, 310 mOsm), gassed with 
carbogen (95% O2, 5% CO2). 270-300 µm thick coronal brain slices were cut in the same 
solution using Leica VT 1200S vibratome. The slices were transferred to the 32
o
C Haas-type 
interface incubation chamber and perfused with Ringer-solution containing (in mM): 124 NaCl, 
3 KCl, 1.25 NaH2PO4*H2O, 2 MgCl2, 2 CaCl2, 26 NaHCO3, 10 glucose; 300 mOsm/kg; 7.4 pH; 
gassed with carbogen. The chamber was gradually cooled down to room temperature.  
3.8. Patch-clamp recordings.  
At least one hour after the preparation, individual slices were transferred to a submerged 
recording chamber mounted on a stage of an up-right microscope (FN-1, Nikon, Japan) equipped 
with infrared differential interference contrast (IR-DIC) filters and a fluorescence light source. 
The slices were kept at room temperature and superfused continuously (~2 ml/min) with 
carbogenated Ringer solution. OPCs were selected for recordings based on the fluorescence: red 
fluorescence (NG2DsRed
+ 
cells) for intact mice, or green and red double-fluorescence 
(GFP
+
NG2DsRed
+ 
cells) for mice injected with retrovirus. Patch pipettes were pulled from 
borosilicate glass capillaries (Science Products, Germany) on a vertical puller (Model PC10, 
Narishige, Japan). Pipettes had resistance of 4.8-7 MOhms when filled with K-gluconate-based 
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internal solution containing (in mM): 125 K-gluconate, 2 Na2ATP, 2 MgCl2, 0.5 EGTA, 10 
HEPES, 20 KCl, 3 NaCl; 280-290 mOsm/kg; titrated to pH 7.3 with KOH. Cells were voltage-
clamped at the holding potential Vh = -80 mV with an EPC-8 amplifier (HEKA, Germany). 
Liquid junction potential was calculated using the software JPCalc for Windows (Peter H. Barry, 
Sydney, Australia) and Vh was corrected for a -13 mV liquid junction potential before seal 
formation. Series resistance was not compensated. After establishing the whole-cell 
configuration, ten depolarizing voltage steps (increment +10 mV) were applied to each cell from 
Vh=-80 mV, and corresponding current responses were recorded in order to verify that the 
selected cell was an OPC [106]. Evoked synaptic currents were elicited with isolated pulse 
stimulator (A-M Systems, Model 2100, Science Products, Germany) using mono-polar glass 
electrode (resistance 5-6 M) filled with Ringer solution and placed at 50-150 µm from the 
recorded cell (Vh=-80 mV). Paired (40 ms inter-pulse interval) monophasic rectangular pulses of 
100-250 µsec duration were applied every 15 sec. Trains of stimuli (20 pulses @ 100 Hz or 20 
pulses @ 25 Hz) were applied each 15 sec. 
For I-V curve recordings, I used a Cs-based internal solution containing (in mM): 100 
CsCH3SO3H (CsMeS), 20 tetraethylammonium (TEA) chloride, 20 HEPES, 10 EGTA, 2 
Na2ATP, and 0.2 NaGTP;  280-290 mOsm/kg; titrated to pH 7.3 with CsOH, and a Ringer 
solution containing (in mM): 119 NaCl, 2.5 KCl, 1 NaH2PO4*H2O, 1.3 MgCl2, 2.5 CaCl2, 26.2 
NaHCO3, 11 glucose; 300 mOsm/kg; 7.4 pH; gassed with carbogen. Spermine (Sigma, 100 µM) 
was included into the internal solution in all recordings of evoked EPSCs in order to test for the 
presence of Ca
2+
-permeable AMPARs in OPCs. Vh was corrected for a -7 mV liquid junction 
potential before seal formation. The cells were held at different potentials (-90, -40, 0, +20, and 
+40 mV) and 10-15 sweeps were recorded at each potential.  
When recording synaptic currents, I applied a voltage step of -5 mV at the beginning of each 
sweep to monitor series resistance. Whole-cells currents in response to voltage steps were low-
pass filtered at 10 kHz and digitized with a sampling frequency of 20 kHz (ITC-18, HEKA 
Instruments Inc, USA). All recordings of synaptic currents were low-pass filtered at 1 kHz and 
digitized with a sampling frequency of 10 kHz. Data acquisition was performed using Recording 
Artist (written by Rick Gerkin, Arizona State University, USA) running under Igor Pro 6.3 
(WaveMetrics, Lake Oswego, USA). All recordings of evoked synaptic currents were performed 
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in the presence of NMDA-receptor antagonist (RS)-3-(2-Carboxypiperazin-4-yl)-propyl-1-
phosphonic acid (CPP, 10 µM, Tocris) and GABAA receptor antagonist (RS)-3-(2-
Carboxypiperazin-4-yl)-propyl-1-phosphonic acid (gabazine, 5 µM, Sigma). In some 
experiments, tetrodotoxin citrate (TTX, 0.5 μM, Abcam) or 6-Cyano-7-nitroquinoxaline-2,3-
dione (CNQX, 10μM, Abcam) was applied at the end of the recording. All drugs were dissolved 
in Ringer solution and applied via the bath. All patch-clamp recordings were performed at room 
temperature. 
3.9. Analysis of electrophysiology data.  
Only those recordings in which the offset drift by the end of the experiment was smaller than ±5 
mV, and the change of the series resistance was < 30% of the original value were considered for 
the analysis. The series resistance was between 20 and 40 M.  
3.9.1. Analysis of evoked EPSCs, I-V curve, and paired-pulse ratio.  
Analysis of evoked EPSCs was performed using custom-written macros in IgorPro. Stimulus 
artefacts were removed using the following procedure: sweeps containing failures (absence of 
postsynaptic response) after the first stimulus, or sweeps recorded in the presence of TTX or 
CNQX, were averaged and the segment of the averaged sweep from time-point of stimulation to 
last point before the second stimulus was cut out, duplicated and concatenated. The resulting 
sweep was subtracted from each recorded sweep.  
To measure the EPSC amplitude (after first or second pulse), I used the following procedure: for 
each recorded sweep the baseline was adjusted to the 100-ms segment immediately preceding the 
stimulation; the peak-center of each event was determined as the time-point at which the first 
derivative of the sweep crossed zero; the amplitude values of the current in the peak-center and 
in 4 points around it (2 points to the right and 2 points to the left) were averaged, and the 
resulting value was taken as current amplitude. The threshold for event detection was determined 
individually for each recorded sweep and was equal to three times the standard deviation of the 
noise. In case several EPSCs occurred after a given stimulus, care was taken to measure the 
amplitude of the first event. 
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Although I used paired-pulse stimulation in all experiments, in order to generate the I-V curve I 
considered only the EPSCs occurring after the first pulse. 10-15 sweeps were recorded at each 
holding potential (-90, -40, 0, +20, +40 mV, and back to -90 mV), the current amplitude in each 
sweep was measured as described above, and all amplitude values at a given holding potential 
were averaged. The resulting averages were used to generate the I-V curve in each cell. To 
calculate the rectification index, the average value of the EPSC amplitude at +40 mV was 
divided by the average value of the EPSC amplitude at -90 mV.  
To determine the paired-pulse ratio, the average amplitude value of the EPSC occurring after the 
second pulse was divided by the average amplitude value of the EPSC occurring after the first 
pulse at a holding potential of -90 mV.  
3.9.2. Analysis of the delayed EPSCs.  
To study the quantal amplitude of synaptic currents in OPCs, I analyzed the delayed EPSCs 
occurring in OPCs after the train stimulation of callosal axons with 20 pulses at 25 or 100 Hz. 
The delayed EPSCs were defined as those with an onset of >10 ms after the last stimulus of the 
train. In each recorded cell I collected the delayed EPSCs in 20-160 sweeps of 1.73-2.3 s length 
each. The EPSCs were detected using a deconvolution-based algorithm [107] in FBrain, a 
customized program running under IgorPro 6 (WaveMetrics, Lake Oswego, USA). FBrain was 
kindly provided by Peter Jonas Lab (IST, Klosterneuburg, Austria). Additional digital high-pass 
(10 Hz) and Notch (50 Hz) filtering was applied to the recorded sweeps in FBrain before the 
analysis. The deconvolution trace was passed through a digital band-pass filter at 0.001 to 200 
Hz. The event detection template had a rise-time of 0.5 ms, a decay time constant of 4 ms, and 
amplitude of -3 pA. The event detection threshold (θ) was set to 4.2 times the standard deviation 
of a Gaussian function fitted to the all-point histogram of the deconvolved trace [107]. All events 
detected by the algorithm were inspected visually, and those events which clearly did not show 
kinetics of typical excitatory postsynaptic currents (i.e. fast rise and exponential decay) were 
manually removed from the subsequent analysis. The subsequent analysis was performed using 
custom-written macros in IgorPro.  
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3.9.3. Cumulative probability histogram of the amplitude of the delayed EPSCs.  
The following procedure was used: (1) The amplitude of all delayed EPSCs was measured in 
each cell as described above; (2) 67 delayed EPSCs were randomly selected from each cell using 
the StatsSample procedure in IgorPro and their amplitude was measured; (3) The amplitude 
distribution of randomly selected events was compared to the amplitude distribution of all events 
within a given cell using the Kolmogorov-Smirnov test in IgorPro to ensure that the two 
distributions were similar, and the pool of randomly selected events was representative of the 
whole population of events. In case the two distributions were found to be different, the random 
selection was automatically repeated by the software in a loop until no difference was found 
between the distributions; (4) In each cell the steps (2)-(3) were repeated 100 times; (5) For each 
of the 100 trials, the randomly selected events from all cells within a given experimental group 
were pooled together to generate an EPSCs amplitude distribution per experimental group; (6) 
For each of the 100 trials this new amplitude distribution of the events in a group of animals 
expressing one of the GluA2-subunit modifying constructs was compared to the GFP group 
using the Kolmogorov-Smirnov test in IgorPro. In selected trials the comparison was repeated 
using SPSS.  
For the data presentation in Figure 4-11 e and Supplementary Figure 4-14 c, I selected one 
representative example for each experimental group out of the 100 trials. The bin size for each 
cumulative probability histogram was 0.5 pA, and each histogram was normalized onto the 
probability density using build-in function in IgorPro. 
3.10. Immunohistochemistry.  
For MBP staining, C57BL/6N mice were sacrificed at P9, P10, P11, P12, P15, and P18. For all 
other stainings, mice were sacrificed 5 days after the retroviral injection. The brain was removed, 
and 350-400 µm thick coronal slices were cut using the Leica VT 1200S vibratome in the 
solution of the following composition (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH2PO4*H2O, 7 MgCl2, 
0.5 CaCl2, 25 NaHCO3, 25 glucose, 75 sucrose. The slices were fixed overnight at 4
o
C in 4% 
paraformaldehyde, dissolved in 10 mM PBS. Then the 350-400 µm thick slices were washed, 
embedded into Agar and re-sectioned in PBS to 30 µm thick slices using a Microtome (HM 
650V, Thermo Scientific). All 30 µm thick slices were inspected visually for quality and for the 
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GFP-expressing (green) cells using an epi-fluorescence microscope (Axio Imager Z1m, Zeiss, 
Germany). Slices which did not contain green cells or appeared damaged were discarded. From 
the remaining pool, 4-12 slices per mouse were selected and used for immunohistochemistry and 
cell counting. All stainings were performed on 30 µm free floating slices placed into multi-well 
plates. For antigen retrieval, I incubated the slices in 10 mM citric acid (pH=6.0) at 37
o
C. After 
washing I applied blocking solution containing: 0.1 M Tris-buffer saline (TBS), 3-5 % Albumin 
Fraction V (Roth), and 0.2-0.5% Triton-X (Roth), at 37
o
C for 1 hour. Slices were incubated with 
primary antibody overnight in blocking solution. The following primary antibodies were used: 
rabbit or guinea pig anti-NG2 (1:500, gift from Bill Stallcup, Burnham Institute, La Jolla, USA), 
mouse anti-APC (1:250, Ab-7, CC-Calbiochem), rabbit anti-Cleaved-Caspase-3 (1:500, Cell 
Signalling Technology), chicken anti-GFP (1:500, Abcam), rat anti-MBP (1:125, Abcam). 
Detection was performed using the following secondary antibodies: goat anti-rabbit Alexa Fluor 
568 (1:500, Invitrogen), goat anti-rabbit Cy5 (1:500, Dianova), goat anti-guinea pig Alexa Fluor 
633 (1:500, Invitrogen), goat anti-mouse Alexa Fluor 555 (1:500, Invitrogen), donkey anti-
chicken FITC (1:1000, Dianova) or goat anti-rat biotin-SP (1:200, Dianova) following by 
streptavidin-Cy3 (1:200, Dianova). Secondary antibody was applied for 3 hours at 37
o
C. For 
EdU visualization I followed the protocol recommended by Thermo Fisher Scientific. For 
counterstaining of the nuclei I used Diamidino-2-phenylindole dihydrochloride (DAPI, 0.2 µg, 
Sigma).  
3.11. Image acquisition. 
A confocal LSM 710 system (Zeiss, Germany) was used for image acquisition. Images 
containing corpus callosum were acquired and saved as z-stacks with 16 bit pixel depth. Each z-
stack was 6-18 µm thick and consisted of 6-18 z-slices; and the z-step was 1 µm. Each layer of a 
z-stack was acquired as a tile-scan (vertical x horizontal: 3 x 7 or 2 x 7 images), where each tile 
was 512 x 512 pixels of size. Pixel size was 0.415 x 0.415 µm. Each tile-scan represented a 
triple-channel fluorescence image, where channels were acquired sequentially in ZEN software 
using 40x oil-immersion objective (NA=1.3). The following excitation laser lines and emission 
detection ranges were used: for DAPI excitation 405 nm, emission 414-490 nm; for FITC 
excitation 488 nm, emission 497-556 nm; for Alexa-555, Alexa-568 or Cy3 excitation 561 nm, 
emission 569-633 nm; for Alexa-633 or Alexa-647 excitation 633 nm, emission 650-740 nm. 
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The beam splitters for each dye matched the excitation laser lines. The pinhole was set to 1.07-
1.42 airy units and adjusted such that the optical section for each channel was 1.2 µm. Laser 
power, detector gain and offset were adjusted such that in the final scan (averaging or average of 
2 frames) I had good signal to background noise ratio. For visualization purpose, few images 
presented in the figures were adjusted for brightness/contrast in ImageJ (NIH, USA), as follows: 
Fig. 4-8 e, brightness for GFP staining; Fig. 4-8 h, brightness and contrast for NG2 and CC1 
staining; Fig 4-8 i, brightness and contrast for CC1 staining; Fig. 4-16 e, brightness for GFP and 
NG2 staining; Fig. 4-16 f, brightness for GFP and NG2 staining; Fig. 4-16 g, brightness and 
contrast in CC1staining; Fig 4-17 b, brightness and contrast for NG2 ; Fig 4-17 c, brightness and 
contrast for CC1; Fig. 4-17 e, brightness for NG2 staining; Fig. 4-17 f, brightness for NG2 
staining; Fig. 4-17 g, contrast for CC1 staining; Fig. 4-22 a, brightness of EdU staining. 
3.12. Cell counting. 
I counted GFP-labeled infected cells in z-stack images using ImageJ Cell Counter plugin (NIH, 
USA). No contrast or brightness adjustment was made in any of the images, but the background 
subtraction was applied to the green channel before counting. For this the background 
fluorescence was measured using linear ‘plot profile’ function in ImageJ and the resulting value 
was subtracted from each pixel of the original image. The ventral and dorsal borders of corpus 
callosum were identified based on the CC1 or NG2 and DAPI staining. To define the lateral 
borders of the region of interest (ROI) used for counting, in each coronal slice I determined the 
midline of the brain and outlined the area of the corpus callosum approximately 500-700 µm to 
each side from the midline. Thus, the ROI spanned 1-1.4 mm along the mediolateral axis of the 
corpus callosum and avoided the cells in the vicinity of lateral ventricles. For the cells located at 
this predefined border of the ROI, only those cells were included in the analysis whose nucleus 
was ≥50% within the border. Cells were counted in 4-12 slices from each mouse and the counts 
within one animal were summed, resulting in 29-486 GFP
+
 cells per animal. OPCs were 
identified as GFP
+
NG2
+
CC1
-
 cells, pre-myelinating oligodendrocytes as GFP
+
NG2
+
CC1
+
 cells, 
and myelinating oligodendrocytes as GFP
+
NG2
-
CC
+
 cells. To avoid individual bias, in randomly 
selected experiments the counting was repeated by one or two additional investigators blind with 
respect to the experimental group of animals. The resulting differences in counts were minor and 
did not affect the final results. 
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3.13. Statistics. 
All data acquisition was randomized (animals for viral injections, cells during patch-clamp 
experiments). Throughout the study I made all efforts to avoid pseudoreplications, both when 
performing experiments in slices and in vivo. For patch-clamp recordings I used in total 59 mice 
of the age P12-17. The exact number of cells and animals used in each experiment are given in 
the figure legends.  
Statistical analysis was performed using SPSS, including tests for homoscedasticity and normal 
distribution. If the datasets had normal distributions and equal variances, one-way ANOVA with 
post-hoc Bonferroni test was used. If the datasets had normal distributions but unequal variances, 
one-way ANOVA with post-hoc Games-Howell test was used. If the datasets were not normally 
distributed, Kruskal-Wallis with post-hoc Dunn’s test was used. To compare values of 
rectification index and paired-pulse ratio between cells in non-injected and the GFP expressing 
animals, I tested the data sets for normal distribution and used the 2-tailed t-test. To compare 
cumulative probability histogram of the amplitude of the delayed EPSCs between control (GFP) 
and each experimental group (“Ca2+-permeable”, “pore-dead”, or “C-tail”), 100 trials of random 
selections were performed and compared in IgorPro as described above. Comparison of the GFP 
and “Ca2+-permeable” groups showed that the two distributions were different in all 100 trials (D 
value > critical value); therefore, I considered the difference between these two distributions 
statistically significant. Comparison of the GFP and “pore-dead” groups showed that the two 
distributions were different in 98 out of 100 trials (D value > critical value); therefore, I 
considered the difference between these two distributions statistically significant. Comparison of 
the GFP and “C-tail” groups showed that the two distributions were different in only 46 out of 
100 trials (D value > critical value); therefore, I considered the difference between these two 
distributions was not statistically significant. To report the corresponding p values in the figure, I 
used the Kolmogorov-Smirnov test in the SPSS. Significance level was set at p<0.05. 
Statistically significant differences are indicated by p values in the figure legends. For graphs, 
each point represents an individual data point and the diamond represents the mean ± SEM. Data 
in the text is also represented as mean ± SEM. 
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4. Results. 
4.1. Construct the recombinant plasmids containing modified GluA2 subunit of AMPARs 
and establish a retroviral delivery approach in vivo for modifying AMPAR function in 
callosal OPCs. 
To target the GluA2 subunit of AMPARs specifically in callosal OPCs in vivo, I employed 
retroviral gene delivery approach, which has been successfully used previously to label 
progenitor cells of OL lineage cells derived from the subventricular zone [93, 108]. Before 
generating the retrovirus carrying the modified GluA2 subunit, it was necessary to construct the 
recombinant retroviral plasmids containing the desired modifications. 
4.1.1. Plasmids used in the study. 
As indicated above, in the present study I used three ways to modify the GluA2-containing 
AMPARs: Ca
2+
-permeable, pore-dead, and C-tail. The constructs of pCI-EGFPGluA2(R583Q) 
(“Ca2+-permeable”) and pEGFPC1-GluA2Ctail (“C-tail”) were the gifts from Roberto Malinow 
(University of California, USA) and from Ingrid Ehrlich (University of Tübingen, Germany),  
respectively. But I had to make the “pore-dead” construct myself. For this, I used mutagenesis 
and made the point mutation from the plasmid of pCI-EGFPGluA2(R583Q) with PCR. After the 
mutagenesis from pCI-EGFPGluA2(R583Q) to pCI-EGFPGluA2(R583E) by PCR, I transformed 
the pCI-EGFPGluA2(R583E) into XL 10-Gold Ultracompetent cells (provided from the kit), 
picked up three different colonies next day, and isolated the plasmid of pCI-EGFPGluA2(R583E) 
from bacteria. After that, I diagnosed the plasmid by using restriction enzymes and analyzed the 
digested fragments by electrophoresis. The purpose was to check whether the plasmid was at the 
desired size. First, I checked the size of entire plasmid by selecting the restriction enzyme which 
cuts the plasmid once (unique cutting site) to linearize the construct. For this purpose the enzyme 
HindIII was chosen. The expected size of pCI-EGFPGluA2(R583E) was 8.218 kbp and the size 
of the fragment on the agarose gel after digestion was above 8 kpb of DNA marker. Second, I 
selected another restriction enzyme which cut the plasmid at multiple sites and yielded multiple 
fragments. For this purpose, I selected the enzyme NdeI which is expected to cut at the sites of 
388, 3398, and 6140 of the sequences of pCI-EGFPGluA2(R583E). Three fragments were 
expected to appear on the agarose gel: 3.01, 2.742, and 2.466 kpb respectively. As a positive 
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control for digestion, I used the pCI-EGFPGluA2(R583Q) plasmid. It served for the comparison 
to make sure that the pattern of fragments after mutagenesis was similar to the input plasmid. 
The negative control for the digestion was the pCI-EGFPGluA2(R583Q) plasmid without 
restriction enzymes. Uncut plasmid is a supercoiled DNA and it appears as three bands at 
different band size on the gel because of different conformation. It is useful to check the 
background of the plasmid on the agarose gel and avoid the false positive result from the 
digested fragments.  
The results from the digestion with Hind III and NdeI are shown in (Fig. 4-1 a). The band size of 
the entire linearized pCI-EGFPGluA2(R583E) plasmid after Hind III digestion (Fig. 4-1 a, lane 
1-3) was between 8-10 kbp of DNA marker and comparable to positive control (Fig. 4-1 a, lane 
P). The bands from pCI-EGFPGluA2(R583E) after the NdeI digestion were of the expected sizes 
and comparable to the positive control (Fig. 4-1 b, lanes 1-3 and P). The bands from the negative 
control, supercoiled uncut pCI-EGFPGluA2(R583Q), were above 5 kbp and thus were far away 
from the sizes of the digested fragments of pCI-EGFPGluA2(R583E)  (Fig. 4-1b, lanes 1-3 and 
N).  
 
 
Figure 4-1. Analysis of digested plasmid 
(pCI-EGFPGluA2(R583E) by restriction 
enzyme using agarose gel electrophoresis. 
(a) The plasmid of pCI-
EGFPGluA2(R583E) was digested by the 
enzyme of Hind III. The digested fragment 
was expected at 8.218 kpb. (b) The same as 
(a) but digested by NedI. The size of three 
fragments was 3.01, 2.742, and 2.466 kpb 
respectively. The gels were truncated for 
clarify. M: 1kb DNA marker; N: negative 
control; P: positive control; 1, 2, 3 denote 
three different colonies. 
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4.1.2. Subcloning the recombinant retroviral vector carrying modified GluA2 subunit.  
I used retroviral approach to deliver modified GluA2 subunit to the callosal OPCs. The retroviral 
vector is based on the Moloney murine leukemia virus (MoMLV).  The cytomegalovirus (CMV) 
promoter was used to drive the transcription of the viral genome. In addition, chicken-beta actin 
(CAG) promoter was used to drive the expression of GFP or a gene of interest (Fig. 4-2) [104]. 
My next goal was to subclone the inserts (“Ca2+-permeable”, “pore-dead”, and “C-tail”) from the 
original vectors (pCI and pEGFPC1) into the retroviral vector based on the cloning site of Agel 
and PmeI (the schematic procedure was shown in Fig. 3-1 in 3.2.2) and to generate new plasmids: 
pRetroCAG-EGFPGluA2(R583Q), pRetroCAG-EGFPGluA2(R583E), and pRetroCAG-
EGFPGluA2(813-862). I also had to verify that (1) the new retroviral plasmids were of the 
correct size, (2) the new retroviral plasmids really contained the insert (“Ca2+-permeable”, “pore-
dead”, or “C-tail”), and (3) the inserts in the new plasmids (pRetroCAG-EGFPGluA2(R583Q), 
pRetroCAG-EGFPGluA2(R583E), and pRetroCAG-EGFPGluA2(813-862)) were inserted in the 
correct orientation (the sequence of insert from 5’ to 3’ to the retroviral vector) after subcloning.  
I used the following restriction enzymes: PmeI in order to linearize each of the plasmids; AgeI 
and PmeI to check the size of the vector and of the insert in each of the three plasmids; PvuII and 
ClaI to verify the correct orientation of the EGFPGluA2(R583Q) and EGFPGluA2(R583E) 
inserts (Fig. 4-3 a); and XhoI to check for the correct orientation of  the EGFPGluA2(813-862) 
insert (Fig. 4-3 b) (Detailed information about the corresponding band sizes after digestion are 
shown in Table 2 within part  3.2.2). Selection of the restriction enzymes for testing the 
orientation of the inserts was based on the following criteria: (a) The enzyme should cut the 
insert at around one third of the total length of insert; (b) The enzyme should avoid digesting in 
the center of the insert and yield two identical fragments in length; (c) The enzyme(s) should 
make one cut in the insert and another cut in the backbone which is close to one side of the insert. 
Taken together, the ideal enzymes for verification of the insert orientation should generate two 
fragments which are different in length.  
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Figure 4-2. Scheme of the recombinant retroviral 
vector. The vector uses cytomegalovirus (CMV) 
promoter (P-CMV) to direct transcription of the viral 
genome and the chicken-beta actin (CAG) promoter to drive the expression of green fluorescent protein 
(GFP). LTR: long terminal repeat; Ψ: viral packing signal; WPRE: Woodchuck hepatitis virus post-
transcriptional regulatory element. 
 
The schematic drawing shown in (Fig. 4-3) explains the digestion sites in the inset and in the 
backbone and indicates the expected size of the fragments. The total length of pRetroCAG-
EGFPGluA2(R583Q) or pRetroCAG-EGFPGluA2(R583E) is 10.6 kbp (Fig. 4-3 a-c). The 
enzyme PvuII cuts at the position around one third in the insert and yields two fragments: 1.77 
kbp and 2.07 kbp (Fig. 4-3 c). In addition, ClaI cuts at the 3’ of WPRE which is located in the 
retroviral backbone (Fig. 4-3 c). The length of WPRE is 0.596 kbp. Therefore, one fragment after 
double enzymatic digestion is expected to be of 8.278 kbp (i.e. length of the retroviral backbone 
minus length of WPRE plus length of the insert which is cut by PvuII) (Fig. 4-3 c). Another 
fragment is expected to be 2.35 kbp (i.e. length of WPRE plus length of the insert cut by PvuII) 
(Fig. 4-3 c). If the insert orientation is wrong (i.e. opposite direction), the expected size of the 
band is 7.977 kbp and 2.67 kbp. To verify the orientation of pRetroCAG-EGFPGluA2(813-862) 
insert, the enzyme XhoI was selected because there are two digestion sites for XhoI in the 
pRetroCAG-EGFPGluA2(813-862) (Fig. 4-3 d-f). One digestion site is within the insert 
EGFPGluA2(813-862) and another is at 3’ of WPRE in the retroviral backbone (Fig. 4-3 d-f). 
Thus, two digested fragments of pRetro-EGFPGluA2(813-862) after XhoI treatment were 
expected: one of 6.935 kbp (i.e. length of the retroviral backbone without the length of  WPRE 
plus length of insert which is cut by XhoI), and another of 0.779 kbp (i.e. length of WPRE plus 
length of the insert cut by PvuII) (Fig. 4-3 f). If the insert orientation is wrong (i.e. opposite 
direction), the expected size of the bands is 6.386 kbp and 1.327 kbp. 
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Figure 4-3. Schematic drawing for verifying the insert orientation in the new generated retroviral 
plasmids.   
(a-c) Description of correct orientation of inserts in pRetroCAG-EGFPGluA2(R583Q) and pRetroCAG-
EGFPGluA2(R583E). (a) The length of the insets was indicated. 5´and 3´: direction of nucleic acids. (b) 
The length of the vector-retroviral backbone. (c) Newly generated retroviral plasmid with the indication 
of the enzyme digestion site to examine the orientation of insert. (d-f) Description of correct orientation of 
insert in pRetroCAG-EGFPGluA2(813-862). (d) As in (a). (e) As in (b). (f) As in (c). 
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The results of the enzymatic digestion are shown in (Fig. 4-4). The entire size of pRetroCAG-
EGFPGluA2(R583Q) and  pRetroCAG-EGFPGluA2(R583E) after linearizing the plasmids with 
PmeI was expected to be 10.64 kbp. Indeed, one band appeared on the agarose gel; it was located 
close to 10 kbp of DNA marker (Fig. 4-4 a, b; lane: PmeI). Upon digestion with PmeI and AgeI, 
there were two bands located at 6.8 kbp and 3.841 kbp on the gel Fig. 4-4a, b; lane: PmeI+AgeI). 
These two bands represented retroviral backbone and insets (EGFPGluA2(R583Q) and 
EGFPGluA2(R583E) in these cases) (Fig. 4-4 a, b; lane: PmeI+AgeI). In the experiments 
designed to verify the insert orientation, and using the enzymes PvuII and ClaI, two bands 
appeared on the gel: close to 8 kbp and 2.5 kbp of DNA marker. These bands corresponded to 
the expected band sizes, i.e. 8.278 kbp and 2.35kbp. It is important to note that the lower band 
was below 2.5 kbp of DNA marker (Fig. 4-4 a, b; lane: PvuII+ClaI). These results indicate that 
the insert orientation in my experiments was correct.  
The entire size of pRetroCAG-EGFPGluA2(813-862) was 7.7 kbp after linearizing the plasmids 
with PmeI (Fig. 4-4 c; lane: PmeI) and the band was appeared close to 8 kbp of DNA marker. In 
the experiments investigating the backbone and the pRetroCAG-EGFPGluA2(813-862) insert, 
two bands were detected on the gel after co-digestion of PmeI and AgeI for examination: one of 
6.8 kbp and another of 0.9 kbp (Fig. 4-4 c; lane: PmeI and AgeI). To test for the insert 
orientation, the plasmid of pRetroCAG-EGFPGluA2(813-862) was digested with XhoI. This 
generated two bands: one was between 6 and 8 kbp of DNA marker and another was close to 1 
kbp of DNA marker (Fig. 4-4 c; lane: XhoI). These bands agree well with the expected band 
sizes of 6.8 kbp and 0.9 kbp, and indicate that the insert orientation in my experiments was 
correct. 
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Figure 4-4. Detection of digested newly generate plasmid (pRetro backbone with insert) by 
restriction enzyme using agarose gel electrophoresis. 
(a) The plasmid of pRetro-GluA2(R583Q) was digested by the enzyme of PmeI, PmeI/AgeI, and 
PvuII/ClaI. The digestion aimed to check the properties of cloned plasmid. (b) The same as (a) but for 
pReto-GluA2(R583E). (c) The plasmid of pRetro-GluA2(813-862) was digested by the enzyme of PmeI, 
PmeI/AgeI, and XhoI. M: 1 kbp DNA marker, N: negative control, input plasmid. 
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4.1.3. GFP expression in HEK 293 cells after transient transfection of retroviral plasmid.  
In each of the constructs containing the modified GluA2 subunit or the GluA2 C-tail the 
sequence of GFP was also present (Fig. 2-1 in the section 2.3) Therefore, my next goal was to 
test whether GFP expression can be detected when each of the plasmids was transiently 
transfected into the HEK 293 cells. In cells transfected with pRetroCAG-EGFPGluA2(R583Q) 
or pRetroCAG-EGFPGluA2(R583E), GFP appeared  in the cytoplasm and close to the cell 
membrane but did not overlap with the nucleus (Fig. 4-5 b, c). In contrast, the pattern of GFP 
expression in cells transfected with pRetroCAG-GFP or pRetroCAG-EGFPGluA2(813-862) was 
different: GFP was visible in the cell cytoplasm and also in the nucleus (Fig. 4-5 a, d). These 
differences of GFP expression pattern may be due to the protein size. The protein size of 
pRetroCAG-GFP and pRetroCAG-EGFPGluA2(813-862) is relatively small, i.e. about 25 and 
34 kDa, respectively. The protein size of pRetroCAG-EGFPGluA2(R583Q) and pRetroCAG-
EGFPGluA2(R583E) is much larger, i.e. about 140 kDa (using DNA sequences calculated by the 
website of http://www.molbiol.ru/eng/scripts/01_06.html, [109]). It has been suggested that 
proteins smaller than 90-110 kDa can passively diffuse through the nuclear pore complex [110]. 
This may explain why in cells transfected with pRetroCAG-GFP and pRetroCAG-
EGFPGluA2(813-862), the GFP expression was detected in the whole cell including in the 
nucleus, while in cells transfected with pRetroCAG-EGFPGluA2(R583Q) and pRetroCAG-
EGFPGluA2(R583E), GFP was found mainly in the cytoplasm (Fig. 4-5).  
Summary of part 4.1. 
Taken together, subcloning of EGFPGluA2(R583Q), EGFPGluA2(R583E), and 
EFGPGluA2(813-862) from original plasmid into retroviral vector was successful and the 
expression of GFP was detected in the HEK 293 cells transfected with  each of the new retroviral 
plasmids. I then used the retroviral plasmids for the further production of retrovirus carrying 
each modifying construct. To simplify the name of each constructs, I named pRetroCAG-GFP, 
pRetroCAG-EGFPGluA2(R583Q), pRetroCAG-EGFPGluA2(R583E), and pRetroCAG-
EGFPGluA2(813-862) hereafter as GFP (control group), “Ca2+-permeable”, “pore-dead”, and 
“C-tail”, respectively. 
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Figure 4-5. The transfection of the retroviral plasmid containing modified GluA2 subunit into HEK 
293 cells and GFP expression was monitored 48 hours after transfection. 
(a) Examples of single plane of confocal images from HEK 293 cells transfected with construct of 
pRetroCAG-GFP showing DAPI, GFP, and merge for two channels. (b) As in (a) but from pRetroCAG-
EGFPGluA2(R583Q). (c) As in (a) but from pRetroCAG-EGFPGluA2(R583E). (d) As in (a) but from 
pRetroCAG-EGFPGluA2(813-862). White arrowheads point to the soma of the transfected cells. Scale 
bar: 10 μm. 
 
 
 
 
 
52 
 
4.2. Changes in synaptic AMPAR-mediated currents in OPCs.  
My next goal was to test whether retrovirus carrying GFP (as a control group) targeted OPCs 
specifically. Next, I expressed three GluA2 subunit modifications, “Ca2+-permeable”, “pore-
dead”, and “C-tail”, in callosal OPCs in vivo using retroviral approach and aimed to investigate 
whether three GluA2 subunit modifications altered the Ca
2+
-permeability and quantal amplitude 
of AMPARs in callosal OPCs due to the changes in the subunits compositions or the 
replacements of AMPARs. For doing that, I applied whole cell voltage clamp technique to record 
the evoked AMPARs mediated current in OPCs upon axonal electrical stimulation (detail 
information is mentioned below) and quantal amplitude by axonal train stimulation. 
4.2.1. Expression of myelin basic protein (MBP) increases gradually in the mouse corpus 
callosum during the second and third postnatal weeks.  
To investigate the importance of AMPAR-mediated signaling for differentiation and 
proliferation of OPCs, the developmental time-window for introducing the modified GluA2 
subunit should be selected such that the rate of OPCs differentiation and proliferation is high. 
There are two reasons for that. First, retrovirus infects proliferating cells. Therefore, in order to 
infect many OPCs, the retrovirus should be injected into the corpus callosum at the time-point 
when many proliferating OPCs are present. Secondly, if I interfere with AMPAR-mediated 
signaling in OPCs during the time-window when differentiation and proliferation rate of OPCs is 
high, it is easier to observe the differences in the experimental groups and the control group. 
During the first 2-3 postnatal weeks, the differentiation and proliferation rate of OPCs is high [9, 
14, 111], and therefore this time-window is suitable for the study. To determine the optimal time-
window more precisely, I performed immunolabeling for MBP in brain slices from mice of P9, 
P10, P11, P12, P15 and P18. MBP is a major myelin protein and is mainly expressed in the 
processes of OLs. Expression of MBP in OLs acts as an indicator of the differentiation of OPCs 
into OLs. 
I found that expression of MBP in the mouse corpus callosum increases gradually between P9 
and P18 indicating that OPCs differentiate into myelinating OLs during this time-window of 
development (Fig.4-6). Therefore, I thought that the age of mice between P10 and P18 would be 
53 
 
the most suitable for modifying AMPAR-mediated on neuron-OPC signaling, and studying the 
effects of modifications on proliferation and differentiation of OPCs. 
 
Figure 4-6. Expression of myelin basic protein in the mouse corpus callosum increases between P9 
and P18. 
Representative overview images of coronal brain slices stained for myelin basic protein (MBP, red). 
Images were taken with a confocal laser scanning microscope using a 10x objective and an optical section 
thickness of 12.3 µm. Slices were prepared from mice of different ages: P9, P10, P11, P12, P15 and P18, 
as indicated on the panels. Dashed lines indicate the borders of each slice. Arrowheads point to the 
midline of the corpus callosum. Scale bar: 1mm. MBP expression is increasing gradually in the corpus 
callosum between P11-P18. Stainings were replicated in three mice of each age-group. 
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4.2.2. GluA2 subunit of AMPARs is present in callosal OPCs in P12-P17. 
It has been reported that callosal OPCs express GluA2-containing Ca
2+
-impermeable AMPARs 
in P7-P8 mice [76] and P8-P16 rats [75]. I wanted to verify these findings in my study and to 
make sure that edited GluA2 subunit of AMPARs is expressed in callosal OPCs during the 
developmental time-window of my interest (P12-P17). For this, I performed whole cell voltage 
clamp recordings from callosal OPCs in NG2DsRed
+
 mice (called “non-injected” hereafter and 
in the figures) and studied evoked AMPARs-mediated currents at several holding potentials (-90 
mV, -40 mV, 0 mV, +20 mV, and +40 mV). After the recording, I built the I-V curve by plotting 
the amplitude of evoked currents vs. holding potential (Fig. 4-7 a), and calculated the 
rectification index as a ratio of current amplitude at Vh of +40 mV and at Vh of -90 mV. If 
GluA2-lacking AMPARs are present in OPCs, it is expected that there are less outward currents 
passing through the receptors when positive holding potentials are applied and polyamine 
spermine (100 µM) is present in the internal solution. In this case, the I-V relationship is 
inwardly rectifying. If AMPARs in OPCs contain GluA2 subunit, I-V curve displays linearity 
because ions flow through the receptors equally good when cells are clamped negative or 
positive potentials. Theoretically if the rectification index is close to 0.44, it is considered that 
AMPARs contains GluA2 subunit; if the rectification index is near 0, it is considered that 
GluA2-lacking AMPARs are present.  
As mentioned above, callosal OPCs in mice express GluA2-containing Ca
2+
-impermeable 
AMPARs during the developmental window of my interest. Therefore, I expected to record 
linear I-V curve and to obtain rectification index close to 0.44. In all experiments polyamine 
spermine was included into the intracellular solution in order to preserve inward rectification of 
I-V relationship. I found that I-V relationship of AMPARs in callosal OPCs showed only slight 
inward rectification, and the averaged rectification index was 0.33±0.058 (Fig. 4-7 b) which was 
close to the index of linear I-V relationship. This data demonstrated that GluA2-containing Ca
2+
-
impermeable AMPARs are indeed present in callosal OPCs in P12-P17 mice.  
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Figure 4-7. Callosal OPCs in P12-17 mice express GluA2-containing AMPARs.  
(a) I-V relationship of evoked axon-glia EPSCs recorded in an OPC from a non-injected mouse. Each 
graph represents one example cell. Each black dot represents the amplitude measurement performed from 
the average of 10 sweeps recorded at a given holding potential (Vh). Corresponding examples of the 
averaged sweeps are shown above each graph. The arrowhead indicates the time of stimulation. The 
stimulation artifacts are blanked for clarity. (b) The summary graph showing rectification index for 
evoked EPSCs recorded in the OPCs from the non-injected (n=6 cells from 5 mice) animals. Each dot 
represents one cell. The black diamonds represent mean ± SEM for each group. The dashed line indicates 
the theoretical rectification index of the linear I-V relationship (no rectification). 
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4.2.3. Retrovirus-GFP targeted oligodendroglia lineage cells specifically. 
Retrovirus infects dividing cells and OPCs are the major cycling cells in the brain [112]. 
However, during second-third postnatal weeks, some other types of proliferating cells may be 
also present in the mouse corpus callosum, in addition to OPCs. In order to test the specificity of 
retrovirus for OPCs, I wanted to find out whether retrovirus infected proliferating cells other than 
OPCs and what the percentage of those cells was. I stereotaxically injected retrovirus-carrying 
GFP (Fig. 4-2) into the corpus callosum of P10-P12 mice (Fig. 4-8 a), sacrificed the injected 
mice 5 days later (Fig. 4-8 b) and performed immunofluorescent labeling for GFP, NG2 and CC1 
to label all infected cells, OPCs and OLs, respectively (Fig. 4-8 f-h). GFP
+
 cells were found in 
the corpus callosum (Fig. 4-8 d) and spread both in medial-lateral and rostro-caudal direction 
from the injection site (Fig. 4-8 c). Remarkably, 94% of the GFP
+
 cells were oligodendrocyte 
lineage cells: 33.3% were OPCs (NG2
+
 GFP
+
) and 43.2% were mature OLs (CC1
+
GFP
+
); the 
remaining 17.4% of cells were weakly positive for both, NG2 and CC1, and I considered them to 
be pre-myelinating oligodendrocytes, i.e. intermediate between OPCs and mature OLs (Fig. 4-8 
f-h). These findings suggested that retrovirus itself infected oligodendrocyte lineage cells 
specifically and infected only few cells of other types.  
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Figure 4-8. Retrovirus targets oligodendroglia lineage cells specifically.  
(a) Stereotaxic coordinates used for bilateral virus injection into the corpus callosum. AP, anteroposterior; 
ML, mediolateral; DV, dorsoventral. (b) Experimental time-frame and animal age. IHC: 
Immunohistochemistry. (c) Scheme showing the distribution of cells targeted with retrovirus (green dots) 
in the corpus callosum. Virally-transduced cells were found in several 300-µm-thick coronal slices along 
the rostro-caudal axis. Cells were counted in 4-12 slices of 30 µm in thickness from each mouse. (d) 
Maximum intensity projection from 6 successive confocal planes showing cells infected with retrovirus 
and expressing GFP in the corpus callosum. Yellow dashed line indicates the area used for counting. 
Scale bar: 100 µm. (e) Diagram showing that the majority of cells targeted with retrovirus (GFP
+
) 
belonged to the oligodendrocyte lineage (n=8 animals). OPCs, oligodendrocyte precursor cells; pre-OLs, 
pre-myelinating oligodendrocytes; OLs, oligodendrocytes. (f) Maximum intensity projection from 3 
successive confocal planes showing quadruple labeling for DAPI, GFP, NG2, and CC1. The arrowhead 
points to an OPC (GFP
+
NG2
+
CC1
-
). Scale bar: 10 µm. (g) Same as in g but the arrowhead points to a pre-
OL (GFP
+
NG2
+
CC1
+
). (h) Same as in g but the arrowhead points to an OL (GFP
+
NG2
-
CC1
+
). 
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4.2.4. Retrovirus infection does not affect AMPAR properties or presynaptic release probability 
at axon-OPC synapses. 
The processes of retroviral infection and GFP expression in OPCs may alter the composition of 
AMPARs and affect their Ca
2+
 permeability. Therefore, I verified the Ca
2+
 permeability of 
AMPARs in callosal OPCs by recording I-V relationship of evoked axon-OPC EPSCs. I 
stereotaxically injected retrovirus carrying GFP into the corpus callosum of P10-P12 
NG2DsRed
+
 mice, sacrificed the animals 3-5 days later (Fig. 4-9), and  performed I-V recordings 
as described above in part 4.2.2.  
I found that current-voltage relationship of AMPARs recorded from GFP
+
 OPCs showed only 
slight inward rectification (Fig. 4-10 a), and the averaged rectification index was 0.35±0.049 
which is comparable to non-injected group (RI=0.33±0.058) (Fig. 4-10 b) (non-injected vs. GFP: 
2-tailed t-test; t(16)=-0.222, p=0.827). This data suggested that GluA2-containing Ca
2+
-
impermeable AMPARs were present in callosal OPCs expressing GFP, and retrovirus infection 
or GFP expression did not alter Ca
2+
-permeability of AMPARs at axon-OPC synapses. 
 
 
Figure 4-9. Experimental time-frame and animal age used for electrophysiological experiments. 
Retrovirus carrying modifications was injected into mouse corpus callosum at P10-12. The 
electrophysiological recordings were performed on the third to fifth days after retroviral injection. 
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Figure 4-10. Retrovirus infection does not affect Ca
2+
-permeability of AMPAR at axon-OPC 
synapses.  
(a) I-V relationship of evoked axon-glia EPSCs recorded in an OPC from a non-injected (left) or a GFP-
injected (right) mouse. Each graph represents one example cell. Each black dot represents the amplitude 
measurement performed from the average of 10 sweeps recorded at a given holding potential (Vh). 
Corresponding examples of the averaged sweeps are shown above each graph. The arrowhead indicates 
the time of stimulation. The stimulation artifacts are blanked for clarity. The I-V curve for the non-
injected group is the same as shown in Figure 4-7. (b) The summary graph showing rectification index for 
evoked EPSCs recorded in the OPCs from the non-injected (n=6 cells from 5 mice) or the GFP-injected 
(n=12 cells from 9 mice) animals. Each dot represents one cell. The black diamonds represent mean ± 
SEM for each group. The dashed line indicates the theoretical rectification index (RI=0.44) of the linear I-
V relationship (no rectification). The dataset for the non-injected group is the same as in the Figure 4-7. 
 
 
 
 
 
 
 
60 
 
The processes of retroviral infection and GFP expression in OPCs may suppress or enhance 
AMPARs trafficking to the postsynaptic membrane in OPCs and to affect the number and/or 
conductance of AMPARs. This would be reflected in the alteration of the amplitude of quantal 
excitatory postsynaptic currents (EPSCs). To address this issue, I studied the amplitude of 
quantal AMPAR-mediated EPSCs in callosal OPCs of non-injected and GFP-injected 
NG2DsRed
+
 mice. I recorded quantal EPSCs (Vh = -80 mV) as delayed currents appearing after 
the train of 20 electrical stimuli applied to callosal axons at 25 or 100 Hz. (Fig. 4-11 a). Delayed 
EPSCs are considered as quantal events in neuronal synapses because those delayed EPSCs have 
amplitude and kinetics similar to miniature EPSCs [113, 114]. Delayed EPSCs after the train of 
electrical stimuli are also considered  as quantal events at axon-OPC synapses due to similarities 
of amplitude and kinetics between mEPSCs and delayed EPSCs [18]. After recording, I selected 
67 delayed events randomly from each cells, pooled the selected events from all OPCs within the 
GFP-group or within the group of non-injected mice, and built the cumulative probability 
histograms (the procedure is described in details in part 3.9.3). These histograms were not 
significantly different between non-injected and GFP-injected mice (Kolmogorov-Smirnov test; 
p=0.470) (Fig. 4-11 b-c). This finding suggested that retrovirus injection and/or GFP expression 
in OPCs did not alter the quantal EPSCs mediated by activation of postsynaptic AMPARs 
(postsynaptic responsiveness to the neurotransmitters) upon release of single glutamatergic 
vesicles from callosal axons. 
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Figure 4-11. Retrovirus does not affect number of AMPAR in OPCs activated upon release of single 
glutamatergic vesicles. 
(a) Top, Representative example trace recorded from an OPC in a non-injected mouse (Vh=-80 mV) after 
cessation of the train stimulation of callosal axons. Stars indicate delayed events. The arrow indicates the 
end of the train stimulation. Bottom, same as the top panel but for an OPC in the GFP group. (b) 
Averaged delayed events from 6 cells (non-infected, left), 7 cells (GFP, right). In each cell, 67 events 
were randomly selected and averaged. Subsequently, the averages from all cells within each experimental 
group were put together to generate the average EPSC for each group. (c) Cumulative probability 
distribution histograms of the amplitude of delayed axon-glia EPSCs. 67 events were randomly selected 
from each cell, and the events from all cells within each experimental group were pooled: non-infected: 
402 events from 6 cells in 4 mice; GFP: 469 events from 7 cells in 6 mice.  
 
62 
 
Next, I wanted to test whether retroviral infection and/or GFP expression affected presynaptic 
part of axon-OPC synapses. To do so, I analyzed paired-pulse ratio (PPR) of evoked axon-glia 
EPSCs. PPR is a measurement of short-term forms of presynaptic plasticity and is widely used to 
estimate the release probability in neuronal field [115, 116]. I recorded the evoked AMPARs-
mediated EPSCs by applying pairs of stimuli at 25 Hz and measured the amplitudes of each 
response in a pair. I then calculated the PPR by dividing the amplitude of the second response by 
the amplitude of the first response, and compared PPR in non-infected and GFP-injected mice 
(Fig. 11a-b). PPR was 1.67±0.19 in non-injected mice and 1.65±0.11in GFP animals, indicating 
that EPSCs in both groups displayed paired-pulse facilitation.  There was no statistically 
significant difference between two groups (2-tailed t-test; t(16)=0.126, p=0.901) indicating that 
retroviral infection or GFP expression did not affect  axonal release probability.  
Taken together, these findings demonstrate that retrovirus infection itself or GFP expression in 
OPCs did not modify the presynaptic release probability, the quantal amplitude, or Ca
2+
 
permeability of the postsynaptic AMPARs in OPCs. Therefore, in subsequent experiments I used 
the animals which received injections of retrovirus expressing GFP alone, as a control group. I 
compared this group to the animals injected with one of GluA2-subunit modifying constructs. 
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Figure 4-12. Retrovirus infection does not affect presynaptic release probability at axon-OPC 
synapses. 
(a) Representative example traces showing evoked axon-glia EPSCs recorded in an OPC (Vh = -90 mV) 
from a non-injected mouse (top) and from a GFP-injected mouse (bottom). Each trace represents the 
average of 30-35 sweeps. The black arrowheads indicate the time-point of stimulation. The stimulation 
artifacts are blanked for clarity. The dashed lines indicate the peak of EPSC elicited by the first stimulus. 
(b) Summary graph showing the paired pulse ratio of the evoked EPSCs recorded in the OPCs. Each dot 
represents one cell. The black diamonds represent mean ± SEM for each group. Non-infected: n=6 cells 
from 5 mice; GFP: n=12 cells from 9 mice.  
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4.2.5. Modifications of the GluA2 subunit of AMPARs in OPCs change rectification and 
amplitude of axon-glia EPSCs. 
To check whether modified GluA2 subunits incorporated into the functional AMPARs in the 
OPCs membrane, I examined the properties of AMPARs in callosal OPCs expressing GluA2-
modifying constructs (Fig. 2-1 b). First, I investigated Ca
2+
-permeability of AMPARs in OPCs 
by recording I-V relationship of AMPAR-mediated EPSCs in OPCs 3-5 days after retroviral 
injection (Fig. 4-9). The I-V relationship of AMPARs-mediated EPSCs from OPCs expressing 
“Ca2+-permeable” construct, displayed noticeable inward rectification (RI=0.093±0.018; Fig. 4-
13 a-b) as expected for Ca
2+
-permeable AMPARs [54]. Inward rectification was significantly 
larger than in GFP group (One-way ANOVA with Games-Howell test; F(3, 30)=11.800, 
p=0.000028; GFP vs. Ca
2+
-permeable: p=0.001 ).  The result indicated that exogenous Ca
2+
-
permeable GluA2 subunit formed functional receptors with or without endogenous subunits and 
integrated into the axon-OPC synapses. Similarly, evoked EPSCs in OPCs expressing “pore-
dead” GluA2 showed marked inward rectification (RI=0.078±0.034; Fig. 4-13 a-b) , indicating 
that Ca
2+
-permeability of AMPARs was significantly larger than in GFP group (One-way 
ANOVA with Games-Howell test; F(3, 30)=11.800, p=0.000028; GFP vs. pore-dead: p=0.002). 
These findings suggested that exogenous subunit replaced the Ca
2+
-impermeable AMPARs, the 
delivery of GluA2-containging AMPARs to the synapses was blocked, and/or additional GluA2-
lacking AMPARs were inserted at the postsynaptic sites in OPCs. Interestingly, nearly linear I-V 
relationship of evoked EPSCs (RI=0.38±0.054; Fig. 4-13 a-b) was obtained from OPCs 
expressing GluA2 “C-tail”, and it was not different from GFP group (One-way ANOVA with 
Games-Howell test; F(3, 30)=11.800, p=0.000028; GFP vs. C-tail: p=0.969). These experiments 
suggested that pore mutations of the GluA2 subunits (“Ca2+-permeable” and “pore-dead”) 
changed the Ca
2+
 permeability of AMPARs resulting from adding more GluA2-lacking 
AMPARs to the postsynaptic site in OPCs. On the contrary, expression of GluA2 “C-tail” did 
not result in changes of Ca
2+
 permeability of AMPARs in OPCs. 
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Figure 4-13. Modifications of the GluA2 subunit of AMPARs in OPCs change rectification of axon-
glia EPSCs. 
(a) Current-voltage (I-V) relationship of evoked axon-glia EPSCs in OPCs infected with a virus carrying 
GFP or one of the AMPAR-modifying constructs. Each graph represents one example cell. Each black 
dot represents an amplitude measurement performed from an average of 10 sweeps recorded at a given 
holding potential (Vh). Corresponding averaged sweeps are shown above each graph. Arrowheads 
indicate time of stimulation. Stimulation artifacts are blanked for clarity. The dataset of GFP is the same 
as in the Figure 4-11. (b) Summary graph showing the rectification index for evoked EPSCs recorded in 
OPCs infected with retrovirus which expresses GFP (n=12 cells from 9 mice), “Ca2+-permeable” GluA2 
(n=8 cells from 7 mice), “pore-dead” GluA (n=6 cells from 6 mice), or “C-tail” of GluA2 (n=8 cells from 
6 mice). Each dot represents one cell. Black diamonds represent mean ± SEM for each group. The dashed 
line indicates the theoretical rectification index (RI=0.44) of the linear I-V relationship (no rectification).  
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Changes in Ca
2+
 permeability of AMPARs in OPCs (Fig. 4-13) represented the differences in the 
combinations of AMPARs after introduced the modified GluA2 subunit in OPCs. These may 
affect the number of AMPARs due to the insertion and/or removal and the conductance of the 
receptors. Therefore, I analyzed the amplitude of the quantal EPSCs occurring after a train of 20 
stimuli at 25 or 100 Hz applied to callosal axons (Fig. 4-14 a), as described above (see part 4.2.4). 
I found that cumulative amplitude distribution histogram of events recorded in OPCs expressing 
“Ca2+-permeable” construct shifted towards the larger amplitudes compared to GFP 
(Kolmogorov-Smirnov test: GFP vs. Ca
2+
-permeable: p=0.00000013492) ( Fig. 4-14 c). These 
data, together with the findings that EPSCs in this group of animals showed strong inward 
rectification (I-V relationship), suggests that increase in the quantal EPSCs amplitude was due to 
a higher conductance of postsynaptic AMPARs composed mainly of Ca
2+
-permeable subunits 
(un-edited GluA2, GluA3, and GluA4, and possibly also GluA1) [117]. 
Comparing the cumulative amplitude distribution histogram between OPCs expressing GFP and 
“pore-dead”, I found that cumulative amplitude distribution histogram was shifted towards the 
larger amplitude in the “pore-dead” group (Kolmogorov-Smirnov test: GFP vs. pore-dead: 
p=0.000006) (Fig. 4-14 b-c), similar to animals expressing “Ca2+-permeable” construct (Fig. 4-
14 b-c). The inwardly rectifying I-V relationship and the larger amplitude in the OPCs with 
GluA2 “pore-dead” expression suggested that additional GluA2-lacking AMPARs were inserted 
to the postsynaptic sites in OPCs (see below in the discussion part for detailed explanations).  
The expression of the GluA2 “C-tail” in OPCs did not affect the quantal EPSC amplitude when 
compared to the GFP group (Kolmogorov-Smirnov test: GFP vs. C-tail: p=0.101) (Fig. 4-14 b-c). 
The findings of un-changed quantal EPSC amplitude and un-changed I-V relationship of the 
evoked EPSCs (Fig. 4-14 a-b), suggest that expression of the GluA2 “C-tail” did not affect the 
ionotropic function or number of AMPARs at individual neuron-OPC synapses. However, I 
cannot exclude the possibility that the GluA2 “C-tail” interfered with intracellular signaling via 
intracellular binding partners as has been proposed  for neuronal synapses [102].  
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Figure 4-14. Modifications of the GluA2 subunit of AMPARs in OPCs change amplitude of axon-
glia EPSCs. 
(a) Left, Representative example traces of EPSCs recorded in OPCs targeted with retrovirus carrying GFP 
or one of the AMPAR-modifying constructs (Vhold=-80 mV). The segments of the sweeps recorded 
immediately after the cessation of train stimulation of callosal axons with 20 pulses at ≥25 Hz are shown. 
Stars indicate delayed events; blue stars indicate events shown on the right. (b) Averaged delayed EPSCs 
from 7 cells (GFP), 7 cells (“Ca2+-permeable”), 8 cells (“pore-dead”), and 8 cells (“C-tail”). In each cell, 
67 events were randomly selected and averaged. Subsequently, the averages from all cells within each 
experimental group were put together to generate the average EPSC for each group. (c) Cumulative 
probability distribution of EPSC amplitudes obtained by pooling 67 randomly selected events from each 
cell within each experimental group. GFP: 469 events (n=7 cells from 6 mice), “Ca2+-permeable”: 469 
events (n=7 cells from 6 mice), “pore-dead”: 536 events (n=8 cells from 6 mice), and “C-tail”: 536 events 
(n=8 cells from 6 mice). The dataset from GFP is the same as in the Figure 4-11.  
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4.2.6. Modifications of the GluA2 subunit of AMPARs in OPCs did not affect paired-pulses ratio 
of EPSCs. 
To test whether modified GluA2 subunits influenced the presynaptic part of axon-OPC synapses, 
I studied PPR, an indicator of the release probability of the presynaptic axons. I found that PPR 
was 1.64±0.11 in GFP group, 1.54±0.156 in “Ca2+-permeable” group, 1.91±0.235 in “pore-dead” 
group, and 2.15±0.23 in “C-tail” group (Fig. 14a-b). There was no statistically significant 
difference between GFP animals and any of the mice expressing GluA2-modifying constructs 
(One-way ANOVA, F(3,30)=2.484, p=0.080) suggesting that the axonal release probability was 
not changed.  
Summary of part 4.2. 
Altogether, AMPARs carrying “Ca2+-permeable” and “pore-dead” modifications of the GluA2 
subunit in callosal OPCs,  inserted to the cell membrane, and this was reflected in the change of 
Ca
2+
-permeability of AMPARs. On the contrary, the expression of GluA2 “C-tail” affected 
neither the ionotropic function of AMPARs, not the quantal amplitude.  
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Figure 4-15. Modifications of the GluA2 subunit of AMPARs in OPCs do not alter the probability 
of the glutamate release from callosal axons. 
(a) Representative example traces showing evoked axon-glia EPSCs (Vh = -90 mV) recorded in OPCs 
expressing GFP or one of the GluA2 subunit modifying constructs. Each trace represents an average of 
10-52 sweeps. Black arrowheads indicate times of stimulation. The stimulation artifacts are blanked for 
clarity. The dashed lines indicate the peak of EPSC elicited by the first stimulus. (b) Summary graph 
showing the paired pulse ratio of the evoked EPSCs recorded in the OPCs. Each dot represents one cell. 
The black diamonds represent mean ± SEM from each group. GFP: n=12 cells from 9 mice; “Ca2+-
permeable”: n=8 cells from 7 mice; “pore-dead”: n=6 cells from 6 mice; and “C-tail”: n=8 cells from 6 
mice. The dataset from GFP is the same as shown in Figure 4-12.  
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4.3. Investigation of the effects of modified GluA2 subunit of AMPARs for differentiation 
and proliferation of callosal OPCs. 
4.3.1. Modifications of the GluA2 subunit of AMPARs decrease OPC differentiation. 
After verifying changes in Ca
2+
 permeability of AMPARs and quantal amplitude of AMPAR-
mediated current in OPCs, I studied the influence of GluA2 subunit modifications on 
differentiation and proliferation of OPCs. I stereotaxically injected retrovirus carrying one of the 
GluA2-subunit-modifying constructs into the corpus callosum of P10-P12 mice and examined 
the stages of oligodendrocyte lineage cells 5 days after the viral injection (Fig. 4-8 a-b) using 
labelling for GFP, NG2, and CC1 (Fig. 4-16, 4-17), as described in 4.2.3 above. I then counted 
the proportion of OPCs, pre-myelinating OLs, and OLs within the total population of cells 
targeted with retrovirus (GFP
+
 cells). I found that the percentage of OPCs (GFP
+
NG2
+
CC1
- 
cells) 
within the population of GFP
+
 cells was remarkably higher in the groups with GluA2 
modifications than in the control group: GFP: 33.25±3.27%; “Ca2+-permeable”: 59.83±1.69%; 
“pore-dead”: 54.50±3.75%; “C-tail”: 53.86±2.56% (One-way ANOVA with post-hoc Bonferroni 
test; F(3, 28)=15.175, p=0.000005; GFP vs. Ca
2+
-permeable: p=0.000008, GFP vs. pore-dead: 
p=0.000143, GFP vs. C-tail: p=0.000146) (Fig. 4-18 a-b). Contrary to the rise in the proportion 
of GFP
+
OPCs, the proportion of OLs (GFP
+
NG2
-
CC1
+ 
cells) was lower in animals with modified 
AMPARs: GFP: 43.18±4.16%; “Ca2+-permeable”: 16.71±2.25%; “pore-dead”: 21.62±3.21%; 
“C-tail”: 23.83±1.33% (One-way ANOVA with post-hoc Bonferroni test; F(3, 28)=15.557, 
p=0.000004; GFP vs. Ca
2+
-permeable: p=0.000006, GFP vs. pore-dead: p=0.000085, GFP vs. C-
tail: p=0.000253)  (Fig. 4-18 a, d). No difference was observed in the percentage of the pre-
myelinating OLs (GFP
+
NG2
+
CC1
+ 
cells) between control group and animals expressing one of 
the GluA2-subunit-modifying constructs: GFP: 17.40±3.59%; “Ca2+-permeable”: 17.69±2.52%; 
“pore-dead”: 16.82±2.48%; “C-tail”: 15.93±2.48% (One-way ANOVA; F(3, 28)=0.077, p=0.972) 
(Fig. 4-18 a, c). It is possible that when OPCs with modified AMPARs start to differentiate, they 
remain at the stage of pre-myelinating OLs longer than the OPCs in the control group of animals. 
These findings suggest that OPCs expressing AMPAR-modifying constructs are less likely to 
differentiate into OLs than OPCs expressing only GFP.  
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Figure 4-16. Oligodendrocyte lineage cells targeted with retrovirus carrying GFP and GluA2 “Ca2+-
permeable” construct. 
(a) Scheme of the differentiation process. (b-d) Examples of the oligodendrocyte lineage cells expressing 
the GFP. Each panel (b-d) represents maximum intensity projection image from 3 successive confocal 
planes showing quadruple labeling for DAPI (blue), GFP (green), CC1 (red), NG2 (white), and merge of 
four channels. OPCs are GFP
+
NG2
+
CC1
- 
(b); pre-myelinating oligodendrocytes are GFP
+
NG2
+
CC1
+
 (c); 
mature oligodendrocytes are GFP
+
NG2
-
CC1
+ 
(d). White arrowheads point to the soma of the infected 
cells. Scale bar: 10 μm. (e-g) As in (b-d) but for the oligodendrocyte lineage cells expressing the “Ca2+-
permeable” construct. 
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Figure 4-17. Oligodendrocyte lineage cells targeted with retrovirus carrying GluA2 “pore-dead” 
and “C-tail” construct. 
(a) Scheme of the differentiation process. (b-d) As in Figure 4-16 b-d but for the oligodendrocyte lineage 
cells expressing the “pore-dead” construct. Scale bar: 10 μm. (e-g) As in Figure 4-16 b-d but for the 
oligodendrocyte lineage cells expressing the “C-tail” construct. 
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Figure 4-18. Modifications of the GluA2 subunit of AMPARs decrease OPC differentiation. 
(a) Scheme of the differentiation process. (b) Summary graph showing the percentage of OPCs (GFP
+ 
NG2
+
CC1
-
)
 within the total population of cells targeted with retrovirus carrying GFP (n=8), “Ca2+-
permeable” (n=7), “pore-dead” (n=8), and “C-tail” (n=9) constructs. Each dot represents one animal. 
Black diamonds represent mean ± SEM for each group. (c) As in (b) but for pre-myelinating 
oligodendrocytes (GFP
+
NG2
+
CC1
+
). (d) As in (b, c) but for mature oligodendrocytes (GFP
+
NG2
-
CC1
+
). 
For (b-d), data from GFP group is the same as in Figure 4-8 e. 
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The lower ratio of GFP
+
OLs in the groups with modified GluA2 subunit was not the 
consequence of differentiation of OPCs into other cell types because the proportion of 
oligodendrocyte lineage cells was similar in all groups: GFP: 93.83±0.95%; “Ca2+-permeable”: 
94.24±1.37%; “pore-dead”: 92.95±0.41%; “C-tail”: 93.63±1.60% ; One-way ANOVA, 
F(3,28)=0.193, p=0.90; Fig. 4-19). It was also not due to the apoptotic cell death through 
activation of caspase3 pathway because the percentage of caspase3
+
GFP
+
 cells in animals with 
modified GluA2 subunit was very low and comparable to GFP control group: GFP: 0.5±0.28%; 
“Ca2+-permeable”: 0.58±0.58%; “pore-dead”: 0%; “C-tail”: 0.23±0.23% (Kruskal-Wallis test; 
H(3)=2.305, p=0.512; Fig. 4-20).  
 
 
Figure 4-19. The differentiation of OPCs expressing GFP or constructs modifying the GluA2 
subunit of AMPARs was restricted in their fate.  
Summary graph showing the proportion of oligodendrocyte lineage cells within the total population of 
cells expressing GFP (n=8 mice), “Ca2+-permeable” (n=7 mice), “pore-dead” (n=8 mice), and “C-tail” 
(n=9 mice) constructs. For this graph, counts of OPCs, pre-OLs, and OLs were pooled from datasets 
shown in Fig. 4-18 b-d. 
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Figure 4-20. Expression of GFP or constructs modifying the GluA2 subunit of AMPARs in OPCs 
does not result in cell death within the corpus callosum. 
(a) Maximum intensity projection from 5 successive confocal planes showing cells expressing “Ca2+-
permeable” construct in the corpus callosum. Arrowheads point to virally-transduced cells. Magenta 
arrowhead points to an infected apoptotic cell (GFP
+
Caspase3
+
), magnified in (c). Yellow arrowheads 
point to infected non-apoptotic cells (GFP
+
Caspase3
-
), magnified in (d). White rectangle indicates a non-
infected apoptotic cell (GFP
-
Caspase3
+
), magnified in (e). Scale bar: 20 µm. (b) The same as in (a), but 
the red channel used for Caspase3 labeling is shown. (c) Higher magnification of the GFP
+
Caspase3
+
 cell 
marked with the magenta arrowhead in (a). Scale bar: 10 μm. (d) Higher magnification of 
(GFP
+
Caspase3
-
) cells marked with the yellow arrowheads in (a). Panels show triple labeling as in 
(c).Scale bar: 10 μm. (e) Higher magnification of the GFP-Caspase3+ cell marked the white rectangle in 
(a). For (c-e), panels show triple labeling for DAPI (blue), GFP (green), Caspase3 (red), and merge. Scale 
bar: 10 μm. (f) Summary graph showing the proportion of GFP+ cells labeled for caspase3 within the total 
population of cells expressing GFP (n=3 mice), “Ca2+-permeable” (n=3 mice), “pore-dead” (n=3 mice), 
and “C-tail” (n=3 mice) constructs. Each dot represents one animal. The black diamonds represent mean 
± SEM for each group.  
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4.3.2. Pore mutations of GluA2 subunit of AMPARs increase OPCs proliferation. 
The increase in the percentage of OPCs within the population of infected GFP
+
 cells in animals 
expressing AMPAR-modifying constructs may be the result of higher proliferation of OPCs, or 
may have occurred because more OPCs left the cycle and entered the resting phase (G0). To 
distinguish between these possibilities, I investigated the proliferation of OPCs expressing 
GluA2-subunit modifying constructs. To label proliferating cells, I used 5-ethynyl-2’-
deoxyuridine (EdU), which is an alternative for 5-bromo-2-deoxyuridine (BrdU), and similar to 
BrdU incorporates into the DNA during the S-phase of the cell cycle [118]. I injected the mice 
intraperitoneally with EdU on the third, fourth, and fifth days after retroviral injection (Fig. 4-21 
a). The interval between EdU injections was 24 hours. I sacrificed the mice on the fifth day, i.e. 
6-7 hours after the third EdU injection, performed immunolabeling for GFP, NG2, and EdU, (Fig. 
4-22) and counted GFP-expressing cells positive for EdU or NG2EdU (Fig. 4-23 a, c).  
 
 
 
Figure 4-21. Schematic drawing of experimental time frame of EdU administration and the 
explanation of OPCs and their progeny carrying EdU.  
(a) Experimental design and timeline for proliferation assay. IHC: Immunohistochemistry. (b) Scheme 
showing a proliferating OPC. Within the oligodendrocyte lineage, EdU incorporates into the DNA of 
proliferating OPCs, and is maintained in their progeny including daughter cells and pre-myelinating OLs 
as well as OLs differentiated from proliferating OPCs. 
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Figure 4-22. EdU
+ 
OPCs in animals injected with retrovirus carrying GluA2-modifying constructs. 
(a) Example of an EdU
+
 OPC in animal injected with retrovirus carrying GFP. The panel represents a 
maximum intensity projection image from 2 successive confocal planes showing quadruple labeling for 
DAPI (blue), GFP (green), EdU (white), NG2 (red), and merge. The arrowhead points to an infected 
EdU
+
 OPC (GFP
+
NG2
+
EdU
+). Scale bar: 10 μm. (b) As in (a) but for the animal injected with retrovirus 
carrying “Ca2+-permeable” construct. (c) As in (a-b) but for the animal injected with retrovirus carrying 
“pore-dead” construct. (d) As in (a-c) but for the animal injected with retrovirus carrying “C-tail” 
construct.  
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I found that point mutations of GluA2 subunit (“Ca2+-permeable” and “pore-dead”) which 
allowed Ca
2+
 to permeate through AMPARs, caused a significant increase in the proportion of 
GFP
+
EdU
+
 within the total population of cells targeted with retrovirus (GFP: 26.81±1.51%; 
“Ca2+-permeable”: 39.94±3.37%; “pore-dead”: 45.31±2.05%; One-way ANOVA with post-hoc 
Bonferroni test; F(3, 27)=14.234, p=0.000009; GFP vs. Ca
2+
-permeable: p=0.001, GFP vs. pore-
dead: p=0.000007; Fig. 4-23 a). Expression of GluA2 “C-tail” did not result in a similar effect 
(“C-tail”: 33.68±1.47%; One-way ANOVA with post-hoc Bonferroni test; F(3, 27)=14.234, 
p=0.000009; GFP vs. C-tail: p=0.174; Fig. 4-23 a). Consistent with the increase in the proportion 
of GFP
+
EdU
+
 within the total population of infected cells (Fig. 4-23 a), I also found the higher 
proportion of NG2
+
EdU
+
 cells within the total population of GFP
+
 cells in mice expressing 
“Ca2+-permeable” and “pore-dead” GluA2, compared to GFP control group (GFP: 20.80±1.02%; 
“Ca2+-permeable”: 33.15±1.70%; “pore-dead”: 37.74±2.22%; Kruskal-Wallis with Dunn’s test; 
H(3)=21.277, p=0.000092; GFP vs. Ca
2+
-permeable: p=0.009, GFP vs. pore-dead: p=0.000084; 
Fig. 4-23 c). Notably, although originally EdU integrates only into the cycling OPCs, it will also 
be carried by the progeny of these OPCs, i.e. daughter cells from proliferating OPCs, as well as 
pre-myelinating OPCs and OLs generated from the newly-born OPCs (Figure 4-21 b). Therefore, 
I could examine whether cycling GFP
+
 cells (GFP
+
EdU
+
) expressing modified GluA2 subunits 
differentiated into pre-myelinating OLs and/or OLs, remained OPCs, or both. I found out that the 
majority of GFP
+
EdU
+
 cells were positive for NG2 in all experimental groups and there was no 
difference from the GFP control group (GFP: 78.34±3.61%; “Ca2+-permeable”: 84.88±4.76%; 
“pore-dead”: 82.93±2.25%; “C-tail”: 79.2±2.15%; Kruskal-Wallis test; H(3)=3.502, p=0.320; 
Fig. 4-23 b). These data suggest that within the timeframe of my experiments, the majority of 
newly-born OPCs remained OPCs (and perhaps some were pre-myelinating OLs), and none of 
the GluA2 modifications specifically promoted the differentiation of newly-born OPCs. 
Retrovirus infected OPCs which were undergoing proliferation. Furthermore, some of the 
GFP
+
OPCs labeled with EdU at the third, fourth, and fifth day after retroviral infection, 
indicating that those EdU
+
OPCs were still proliferating. This means that infected EdU
+
OPCs 
entered the cell cycle again and underwent cell division for the second time. Hence, increased 
number of EdU
+
 cells in animals with “Ca2+-permeable” and “pored-dead” modifications 
indicates that these modifications triggered OPC to undergo another cell division. If increased 
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Ca
2+
 permeability of AMPARs triggers another cell division, but does not increase the proportion 
of newly-born pre-myelinating OLs and/or OLs, then the population of GFP
+
NG2
+
 cells in 
animals with these modifications should contain more cycling cells and/or cells that have 
recently completed the cell cycle, i.e. EdU
+
 cells, than in the “C-tail” or GFP groups. However, I 
found this to be the case only for the “pore-dead”, but not the “Ca2+-permeable” mutation (GFP: 
41.11±1.69%; “Ca2+-permeable”: 43.54±2.95%; “pore-dead”: 52.51±2.76%; “C-tail”: 
39.72±2.42%; One-way ANOVA with post-hoc Bonferroni test; F(3, 27)=5.569, p=0.004; GFP 
vs. Ca
2+
-permeable: p=1, GFP vs. pore-dead: p=0.016, GFP vs. C-tail: p=1, pore-dead vs. C-tail: 
p=0.006; Fig. 4-23 d). This suggests that expression of “pore-dead”, but not “Ca2+-permeable”, 
GluA2-containing AMPARs expedited the OPC cell cycle time and probably prompted OPCs to 
start another cell division (i.e. the third time). Although “Ca2+-permeable” and “pore-dead” 
modifications resulted in very similar electrophysiological changes at axon-OPC synapses (Fig. 
4-13, 4-14), it is possible that the signaling cascades downstream of the AMPARs differ in these 
two situations resulting in a dissimilar effects of the two modifications on the number of cycling 
cells within the NG2
+
GFP
+
 population (Fig. 4-23 d). 
Summary part of 4.3. 
Taken together, all three modifications of GluA2 subunit resulted in the decrease of 
differentiation of OPCs. The increase in the proportion of proliferating cells was observed only 
in animals with point mutations of GluA2 subunit which enhanced the permeability of AMPARs 
for Ca
2+. Interestingly, “pore-dead” modification had stronger effect on proliferation of OPCs 
than “Ca2+-permeable” modification, had a dissimilar effect on the proliferation.  
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Figure 4-23. Modifications of the GluA2 subunit of AMPARs increase OPCs proliferation.  
(a) Summary graph showing the proportion of GFP
+
EdU
+
 cells within the total population of cells 
targeted with retrovirus (GFP
+) expressing GFP (n=8), “Ca2+-permeable” (n=7), “pore-dead” (n=8), and 
“C-tail” (n=8) AMPAR-modifying constructs. Each dot represents one animal. Black diamonds represent 
mean ± SEM for each group. (b) As in (a) but for the proportion of GFP
+
NG2
+
EdU
+
 cells within the 
population of GFP
+
EdU
+
 cells. (c) As in (a-b) but for the proportion of NG2
+
EdU
+
cells within the 
population of
 
 GFP
+
 cells. (d) As in (a-c) but for the proportion of GFP
+
NG2
+
EdU
+
 cells within the 
population of GFP
+
NG2
+
 cells.  
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5. Discussion. 
The major findings of the present study are: (1) Introduced point mutations of GluA2 subunit 
(“Ca2+-permeable” and “pore-dead”) altered Ca2+ permeability of AMPARs in OPCs; (2) 
Alteration of Ca
2+
 permeability of AMPARs in OPCs reduced their differentiation into OLs but 
promoted their self-renewal by proliferation; (3) Expression of GluA2 “C-tail” in OPCs did not 
change Ca
2+
 permeability and quantal amplitude of AMPARs, however, the differentiation of 
OPCs was suppressed.  
Below I discuss possible trafficking pathways of AMPARs in OPCs and potential reasons for the 
change in the differentiation and proliferation in OPCs upon modifications of AMPAR properties.  
5.1. Possible subunit composition and trafficking of AMPARs containing the modified GluA2 
subunit in OPCs.  
Based on the published evidences regarding expression of different AMPARs subunits in OPCs 
and trafficking of AMPARs in neurons, it is interesting to speculate how the modified subunits 
assembled into homo- or hetero-tertamers to form AMPARs in OPCs in my experiments. 
5.1.1 GluA2(R583Q) mutation (“Ca2+-permeable”).  
In my study I observed that during the second-third postnatal week, evoked axon-glia AMPARs-
mediated EPSCs recorded from callosal OPCs displayed nearly linear I-V relationship (Fig. 4-7) 
suggesting that OPCs contained little/no Ca
2+
-permeable AMPARs. Introducing Ca
2+
-permeable 
GluA2 subunit with point mutation (GluA2(R583Q)) at the channel pore to the OPCs resulted in 
strongly inwardly rectifying I-V relationship of evoked axon-glia EPSCs (Fig.4-13) and 
increased amplitude of quantal axon-glial EPSCs (Fig. 4-14). Evidence from the literature shows 
that when Ca
2+
 permeable unedited GluA2 subunit is introduced to neurons by viral approach, I-
V relationship of EPSCs recorded from the infected neurons display stronger inward rectification 
than in non-infected neurons [119-121]. This corresponds well to the findings of my study. 
Furthermore, several studies have shown that Ca
2+
-permeable AMPARs have higher single-
channel conductance than Ca
2+
-impermeable AMPARs containing edited GluA2. For example, 
this has been observed in HEK 293 cells, when single-channel conductance was compared in 
cells expressing recombinant GluA2/GluA4 vs. unedited GluA2/GluA4 receptors, as well as in 
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cortical layer 2/3 pyramidal cells [117, 122]. Therefore increase in the quantal amplitude of 
EPSCs, which I observed in OPCs expressing GluA2(R583Q) subunit, may reflect to the fact 
that Ca
2+
-permeable AMPARs have higher single-channel conductance.  
What can be the subunit composition of AMPARs containing GluA2 subunit with GluA2(R583Q) 
point mutation in my experiments? Several earlier studies using in situ hybridization, Northern 
blot, Southern blot, RT-PCR, RNA-Sequencing transcriptome, Western blot, and 
immunolabeling indicate that mRNAs and protein for GluA1, GluA2, GluA3, and GluA4 
subunits of AMPARs are present  in the purified O-2A progenitor cells, CG-4 progenitor cell line, 
and/or in OPCs from several brain regions of the developing rodents, although the expression of 
GluA1 subunit was reported to be very low [20, 61-72, 123]. It is also known that AMPARs 
subunits preferentially assemble as receptors containing either two GluA2 or no GluA2 subunits 
[50]. Keeping in mind that AMPARs are tetramers and assuming that OPCs lack GluA1 subunit, 
the possible combinations of AMPARs subunits in OPCs during physiological conditions can be: 
GluA2/3, GluA2/4, or GluA3/4 (Fig. 5-1). If recombinant GluA2 subunits with pore mutation are 
introduced to the callosal OPCs, the mutated subunits may form homo-tetramers and/or hetero-
tetramers with endogenous subunits. Probable resulting subunit combinations of AMPARs are 
shown in (Fig. 5-2). Subunits with  GluA2(R583Q) point mutation can form Ca
2+ 
permeable 
AMPARs, but can also assemble into Ca
2+
-impermeable tetrameric AMPARs if GluA2(R583Q) 
subunits combine with endogenous GluA2 (Fig. 5-2 Left). Nevertheless, the number of possible 
combinations of Ca
2+
-permeable AMPARs is higher (4 possible combinations; Fig. 5-2 Right) 
than the number of combinations of Ca
2+
-impermeable AMPARs (3 possible combinations; Fig. 
5-2 Left). 
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Figure 5-1. Possible combinations of AMPARs present in OPCs.  
2, 3, and 4 designate GluA2, GluA3, and GluA4 respectively. 
 
 
 
Figure. 5-2 Possible combinations of AMPARs after GluA2(R583Q) is introduced to OPCs. 
(Left) Combinations of Ca
2+
-impermeable AMPARs. (Right) Combinations of Ca
2+
-permeable AMPARs. 
2, 3, 4, and 2Q designate GluA2, GluA3, GluA4, and GluA2(R583Q) respectively. Blue dash rectangles 
indicate the possible homo- and hetero-tetrameric AMPARs containing GluA2(R583Q) subunit.  
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How did AMPARs containing GluA2 subunit with GluA2(R583Q) point mutation traffic to the 
synaptic sites of axon-OPC synapses? In neurons, AMPARs are assembled as hetero-tetramers of 
GluA1/2 or GluA2/3 subunits and traffic to synapses in a subunit-specific way depending on the 
intracellular C-terminal domain of the subunits. GluA1 and GluA4 subunits contain long C-
terminal domain and GluA3 contains short C-terminal domain, while GluA2 subunit can contain 
either short or long C-terminal domain [124]. AMPARs containing subunits with long C-
terminal domain are delivered to synapses exclusively in activity-dependent way [125-127], 
while AMPARs containing subunits with short C-terminal domain continuously incorporate into 
synapses and replace the existing AMPARs [119]. For hetero-tetrameric AMPARs, the type of 
trafficking (continuous or activity-dependent) is determined by the subunit with long C-terminal 
domain [119]. Do AMPARs in OPCs traffic to the synapses in the similar fashion as in neurons? 
It is possible that trafficking of homo- or/and hetero-tetrameric AMPARs in OPCs follows the 
rules discovered in neurons [119, 125-127], and AMPARs containing GluA2(R583Q) were 
continuously delivered to axon-OPC synapses and substituted the existing GluA2-containing 
AMPARs. As a result, the amount of edited GluA2-containing receptors was reduced and the 
amount of Ca
2+
-permeable AMPARs, which have higher single-channel conductance [117], was 
increased. This insertion and replacement of receptors resulted in the inwardly rectifying I-V 
relationship and in the larger amplitude of quantal EPSCs (Fig. 4-13, 4-14). However, based on 
my data I cannot fully rule out the possibility that the existing GluA2-containing AMPARs were 
not removed. Hence, the second possibility is that newly-assembled AMPARs containing 
GluA2(R583Q), were simply added to the postsynaptic sites of axon-OPC synapses without 
removal of the existing GluA2-containing AMPARs. In this scenario, the increased total number 
of the postsynaptic AMPARs may have contributed to the larger quantal amplitude (in addition 
to the increased single-channel conductance of Ca
2+
-permeable AMPARs). Furthermore, as 
added receptors containing GluA2(R583Q) subunit, three out of four are permeable for Ca
2+
 
(indicated as blue dash rectangles)
 
(Fig. 5-2). Thus, additional receptors containing 
GluA2(R583Q) subunit enhanced the permeation of Ca
2+
 and resulted in the inwardly rectifying 
I-V relationship (Fig. 4-13). Along this line, it has been observed that in the CA1 region of the 
P5-7 rat hippocampus, neurons have Ca
2+
-permeable AMPARs, but larger quantal EPSCs 
(compared to  P8-18 rats) is due to the higher number of activated receptors rather than to the 
higher single-channel conductance [128].  
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5.1.2. GluA2(R583E) mutation (“pore-dead”). 
In my study I found that expression of GluA2(R583E) construct (“pore-dead”) resulted in 
increased Ca
2+
 permeability of AMPARs and increased amplitude of quantal EPSCs. This result 
was not fully predicted because presence of AMPARs containing pore-dead subunits (which 
have low/no conductance) at synapses is intuitively expected to reduce the amplitude of 
AMPAR-mediated EPSCs. Indeed, it has been reported that expression of recombinant 
GluA3(Q613E) subunit of AMPARs, carrying pore-dead mutation at the Q/R site, in oocytes 
resulted in non-conducting AMPARs [101]. Moreover, co-expressing recombinant pore-dead 
GluA3(Q612E) subunit together with conducting GluA1 subunit in oocytes caused attenuation of 
the current response evoked by application of 300 µM kainate, when compared with the 
expression of GluA1 together with GluA3 subunit [101]. This study indicated that reduced 
response amplitude may result from the activity of homomeric GluA1 receptors, or from the 
heteromeric receptors of GluA3(Q612E) with GluA1. Furthermore, expression of the pore-dead 
mutant GluA2(R586E) in hippocampal pyramidal neuron reduced the amplitude of AMPARs-
mediated EPSCs compared to pyramidal neurons without expression of the pore-dead construct 
of GluA2 subunit [119].  
In my study, when recombinant pore mutation of GluA2(R583E) subunits was introduced into 
OPCs, the modified subunits may have formed homo-tetramers and/or hetero-tetramers with 
endogenous AMPAR subunits. The resulting possible combinations of AMPARs are shown in 
(Fig. 5-3). Three groups of receptors could be formed: Ca
2+
-impermeable (Fig. 5-3 Left), Ca
2+
-
permeable (Fig. 5-3 Middle), and non-conducting (Fig. 5-3 Right). Remarkably, heteromeric 
receptors composed by conducting GluA2 and pore-dead GluA2(R583E) (Fig. 5-3 Left) are 
likely to have very small single-channel conductance because single-channel conductance of 
edited GluA2 receptors is ~ 300 fS [117]. Taking together, I expected that in my study AMPARs 
in OPCs expressing pore-dead GluA2(R583E) subunit would be permeable to ions but would 
allow only reduced flow of ions. However, the results of my electrophysiological experiments 
appeared more complicated because they showed increase rather than decrease of EPSC 
amplitude in OPCs with GluA2(R583E) mutation, and also change in I-V rectification (Fig. 4-13, 
Fig. 4-14). 
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Figure. 5-3 Possible combinations of AMPARs after GluA2(R583E) is introduced to OPCs. 
(Left) Combinations of Ca
2+
-impermeable AMPARs. (Middle) Combinations of Ca
2+
-permeable 
AMPARs. (Left) Non-conducted of AMPARs. 2, 3, 4, and 2E designate GluA2, GluA3, GluA4, and 
GluA2(R583E) respectively. Red dash rectangles indicate the possible homo- and hetero-tetrameric 
AMPARs containing GluA2(R583E) subunit. 
 
Below I discuss several possibilities regarding the trafficking of GluA2(R583E)-containing 
AMPARs in OPCs, try to speculate whether GluA2(R583E)-containing AMPARs were delivered 
to the postsynaptic sites of axon-OPC synapses, and whether they substituted the existing 
AMPARs, or they were simply added to the postsynaptic sites. I then try to interpret the results 
of my electrophysiological findings based on these ideas. 
First possibility is that trafficking of homo- or/and hetero-tetrameric AMPARs in OPCs follows 
the rules discovered in neurons [119, 125-127]. In this scenario, AMPARs containing 
GluA2(R583E) subunit would be delivered to axon-OPC synapses and substitute the existing 
AMPARs (Fig. 5-4 top). As in (Fig. 5-4 top), for instance, two GluA2-containing AMPARs (Fig. 
5-4 top left) could be replaced by two GluA2(R583E)-containing AMPARs, derived from four 
possible combinations (Fig. 5-4 top right, indicated as red dash rectangle). However, as those 
two GluA2(R583E)-containing AMPARs have low/no conductance, the cell may compensate for 
this fast by inserting the endogenous AMPARs with higher conductance, e.g. GluA3/4. As a 
result, the amount of edited GluA2-containing receptors would be reduced, and the amount of 
Ca
2+
-permeable AMPARs, which have higher single-channel conductance [117], would be 
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increased. These insertion and replacement of receptors resulted in the inwardly rectifying I-V 
relationship and larger amplitude of quantal EPSCs.  
Second possibility is that GluA2(R583E)-containing AMPARs were not inserted to synapses but 
expression of GluA2(R583E) pore-dead subunits triggered the substitution of endogenous 
GluA2-containing AMPARs by GluA2-lacking AMPARs, e.g. receptors comprised of GluA3/4 
subunits (Fig. 5-4 middle). In this case, inwardly rectifying I-V relationship of axon-OPC EPSCs 
(Fig. 4-13) would be explained by the absence of GluA2 subunits, and the larger quantal 
amplitude (Fig. 4-14) would be explained by higher single-channel conductance of GluA2-
lacking receptors and/or by higher numbers of GluA2-lacking receptors.  
Third possibility is that GluA2(R583E)-containing AMPARs were delivered and incorporated 
into the synapses but the existing AMPARs were not removed  (Fig. 5-4 Bottom). In this scenario, 
inwardly rectifying I-V relationship may be due to the fact that the amount of Ca
2+
-permeable 
AMPARs was higher than Ca
2+
-impermeable AMPARs (3 out of 5 functional channels) (Fig. 5-
3). In addition, the increased number of AMPARs (possible combinations are indicated in Fig. 5-
3) may have led to the larger quantal amplitude.  
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Figure. 5-4 Three possibilities of subunits compositions of AMPARs after introducing 
GluA2(R583E) to OPCs. 
(Top) Schematic drawing showing that existing AMPARs may be replaced by the AMPARs with new 
combinations of subunits (red dash rectangle) after introducing GluA2(R583E) in OPCs. (Middle) 
Schematic drawing showing that existing GluA2-containing AMPARs may be removed; this may be 
accompanied by insertion of endogenous GluA3/4 subunits (in the right). (Bottom) Schematic drawing 
showing that pore-dead GluA2(R583E)-containing AMPARs may be inserted  into the postsynaptic site 
of axon-OPC synapses (in the right) while the endogenous subunits do not get removed. 
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5.1.3. GluA2(813-862 ) (“C-tail”) modification of the GluA2 subunit. 
The expression of GluA2 “C-tail” affected neither Ca2+ permeability of AMPARs nor the 
amplitude of quantal axon-glia EPSCs (Fig. 4-13, 4-14). These results were different from the 
hippocampal pyramidal neurons, where expression of the GluA2 “C-tail” resulted in a decrease 
of the amplitude of synaptic AMPAR-mediated currents [119]. There may be several 
explanations why no electrophysiological changes were observed at synapses between axons and 
OPCs expressing GluA2 C-tail in my study:  
(1) As indicated above, AMPARs traffic to synapses in a subunit-specific way depending on the 
intracellular C-terminal domain of the subunits. In general, if an AMPAR is composed of 
subunits with long and short intracellular C-terminal domain, trafficking is determined by the 
subunits with long intracellular C-terminal [119]. For example, for heteromeric GluA1/2 
AMPARs trafficking is determined by GluA1 subunit which contains long C-terminal domain, 
and therefore these receptors traffic to synapses in an activity-dependent way [125-127]. If 
heteromeric GluA2/3 AMPARs are assembled, both GluA2 and GluA3 contain short C-terminal 
domain, therefore these receptors can continuously incorporate into synapses and replace the 
existing AMPARs [119]. Expression of GluA2 “C-tail”, i.e. the short C-terminus, in my 
experiments may have prevented the continuous synaptic delivery of endogenous AMPARs to 
the synapse, and in particular the delivery of hetero-tetrameric GluA2/3 receptors could have 
been affected. As a consequence, no new AMPARs were inserted into the postsynaptic sites, and 
therefore no existing AMPARs were removed from the synapse.  
(2) Expression of GluA2 “C-tail” in OPCs prevented the synaptic delivery of endogenous 
AMPARs to the synapse, but the “missing” receptors were rapidly replenished from the pool of 
extrasynaptic AMPARs by lateral diffusion. 
(3) It is currently not known whether OPCs express GluA2 subunit with short (GluA2short) or 
with long (GluA2long) C-terminus. If they contain only GluA2long, the trafficking of AMPARs 
with this subunit may be activity-dependent, in analogy to neurons [127]. As I expressed short 
“C-tail” of the GluA2 subunit, this could have no effect on the delivery of the endogenous 
GluA2long-containing AMPARs to axon-OPC synapses. 
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(4) The trafficking of GluA2-containing AMPARs in OPCs, mainly those with GluA2/3 subunits, 
did not depend on the interaction between the GluA2 C-terminus and AMPAR-binding proteins. 
Along this line, it has been demonstrated that in hippocampal neurons the recombinant GluA2 
subunit without C-tail is able to traffic to synapse, thus suggesting that GluA2 C-tail may not 
necessarily be required for the trafficking of GluA2-containing AMPARs [129].  
It is important to note that electrophysiological parameters which I have studied, aimed to 
investigate changes in the ionotropic function of postsynaptic AMPARs. Absence of those 
changes in OPCs expressing GluA2 “C-tail” does not mean that GluA2(813-862) construct has 
not modified physiology of the cells. For example, as indicated in the “Results” section, it is 
possible that GluA2 “C-tail” interfered with intracellular signaling via intracellular binding 
partners as has been proposed for neuronal synapses [102]. 
Taking together, up to now the trafficking mechanisms of AMPARs in OPCs are poorly 
understood, and my results provide some new insights regarding AMPARs trafficking in OPCs. 
My data suggest that expression of recombinant GluA2 subunits carrying point-mutations in the 
channel pore resulted in delivery and incorporation of these subunits into the postsynaptic sites 
of axon-OPC synapses in the corpus callosum. This may, or may not, have been accompanied by 
the removal of the existing AMPARs. As a result, I have observed changes in the inward 
rectification of the I-V relationship of axon-OPC EPSCs and a shift of the cumulative histogram 
of quantal amplitude to larger values. Expression of GluA2 “C-tail”, the GluA2(813-862), in 
OPCs did not result in changes of I-V rectification or quantal amplitude, and different reasons 
can explain this finding. Importantly, the combinations of AMPARs subunits in OPCs are most 
likely not similar to neurons: the majority of AMPARs in neurons are composed of GluA1/A2 
and/or GluA2/A3 subunits [48], but the expression of GluA1 subunit in OPCs is low [65]. 
Therefore, AMPARs in OPCs are likely composed of GluA2/A3, GluA2/A4, and GluA3/4 
subunits. The composition of AMPARs also determine the ways of their trafficking [130], and 
therefore trafficking of AMPARs in OPCs is likely different from neurons. 
AMPARs mediate most synaptic excitation, participate in synaptic plasticity, and play a role in 
epilepsy and many other diseases. In particular, it has been shown that AMPARs are among the 
important molecular targets in the therapy of epilepsy [131]. As AMPARs mediate synaptic 
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currents between neurons and OPCs, the signaling pathways which they initiate may be essential 
for remyelination [91-93]. Therefore, it is important to carry out further research aimed at 
understanding the subunit composition of AMPARs and their trafficking pathways in OPCs. 
These knowledges can help the development of the new therapeutic strategies for treatment of 
myelin-related diseases. 
5.2. Differentiation and proliferation of OPCs are influenced by AMPARs. 
5.2.1. Role of Ca
2+
 for proliferation of OPCs. 
Several studies indicated that AMPARs are involved in regulation of the differentiation and 
proliferation of OPCs in cell culture [33, 69, 95, 132]. However, it is so far not clear whether 
synaptic currents mediated by AMPARs in OPCs regulate their maturation or cell division. The 
findings of the present study demonstrate that introducing point mutation GluA2(R583Q) or 
GluA2(R583E) in the channel pore of the GluA2 subunit of AMPARs in callosal OPCs in vivo 
during the peak of myelination in the corpus callosum (i.e. second-third postnatal weeks), 
enhances Ca
2+
 permeability of AMPARs (Fig. 4-13). This, in turn, leads to increased 
proliferation of OPCs and reduces their differentiation into OLs. Ca
2+
 is known as secondary 
messenger and is involved in cell cycle regulation, migration, and differentiation of neural cells 
and oligodendrocyte lineage cells [133, 134]. Increase of cytoplasmic Ca
2+
 level ([Ca
2+
]i) in 
OPCs can occur through several pathways, and activation of Ca
2+
-permeable AMPARs is one of 
them (Fig. 5-5). Elevation of [Ca
2+
]i is known to affect the activity of cyclin-dependent kinase 
activating kinases (CAKs) or cyclin-dependent kinases inhibitors (CKIs); the cell cycle 
progression, or cell cycle exit followed by differentiation, depends on the balance between these 
two mechanisms [134]. Therefore, too high or too low Ca
2+
 entry through AMPARs during 
physiological and/or pathological conditions may affect self-renewal of OPCs and/or their 
differentiation in OLs, and may also cause imbalance between differentiation and proliferation. 
Interestingly, I found that “pore-dead” mutation of GluA2 subunit expedited the cell cycle time 
of OPCs more than “Ca2+-permeable” mutation (Fig. 4-23 d), although both modifications 
resulted in very similar electrophysiological changes at neuron-OPC synapses (Fig. 4-13, 4-14). 
The difference may result from the subunit compositions or the location of AMPARs. 
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Alternatively, or additionally, these two modifications may trigger distinct signaling cascades 
downstream of the AMPARs.  
 
Figure 5-5. Scheme showing possible signaling pathways of Ca
2+
 entry to activate the cell cycle 
progression. 
AC: adenylate cyclase; CAKs: cyclin-dependent kinase activating kinases; CaM-K: calmodulin kinase; 
CKIs: cyclin-dependent kinases inhibitors; DAG: diacylglycerol; ERK/MAPK: extracellular signal-
regulated kinase/mitogen-activated protein kinase; PKC: protein kinase C; PLC: phospholipase C. From  
[134].  
 
5.2.2. Possible role of non-ionotropic function of AMPARs for differentiation of OPCs. 
The findings of the present study point to the fact that ionotropic function of AMPARs is not the 
only mechanism regulating OPC differentiation, because expression of GluA2 “C-tail” most 
likely altered differentiation of OPCs via a distinct mechanism. It has been reported that 
expressing β3 integrin in CG-4 cells line or in OPCs isolated from neonatal rat brain, inhibits 
differentiation of OPCs to MBP-positive cells [135]. Furthermore, the expression of integrin was 
regulated developmentally during differentiation of OPCs, i.e. αvβ1 integrin was downregulated 
during differentiation [136]. GluA2 subunit of AMPARs forms a complex with myelin 
proteolipid protein (PLP)-integrin in OPCs [70]. Moreover, it has been reported that β3 integrin 
interacts with GluA2 subunit directly with their cytoplasmic domain and regulates the expression 
of cell-surface AMPARs in hippocampal neurons [137]. It is possible that “Ca2+-permeable” or 
“pore-dead” GluA2 subunits, or the GluA2(813-826) “C-tail”, in OPCs bound to integrin and 
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affected the ability of integrin to regulate OPCs differentiation by yet un-identified mechanism.  
This possible protein-protein interaction may explain how the GluA2(813-826) “C-tail”, which 
did not alter ionotropic function of AMPARs in OPCs, reduced their differentiation in the 
present study. In the future, it would be interesting to investigate interaction between AMPARs 
and integrins, and to find out whether these interactions represent a mechanism modulating the 
development of OPCs. 
5.2.3. Energy consumption may contribute to reduced differentiation in OPCs expressing 
modified GluA2 subunits of AMPARs. 
According to general concept of energy use in the brain, the majority of energy is consumed for 
synaptic transmission (synaptic signaling), and “housekeeping” (non-signaling) processes, i.e. 
protein synthesis and/or protein turnover [138, 139]. Expression of exogenous subunits of 
AMPARs in OPCs may have resulted in additional energy consumption, i.e. for synthesis and 
turnover (insertion and removal from the synapse) of the added receptors. This may have 
contributed to the suppression of differentiation of OPCs. However, it is possible that observed 
reduction in differentiation of OCPs was short-term, and once the balance of energy consumption 
in OPCs has been re-adjusted, the process of differentiation of OPCs into mature OLs can be re-
started and catches up with the loss of mature OLs. In the present study, I monitored the change 
in differentiation of OPCs 5 days after retroviral injection. As a next step, it would be interesting 
to check whether the decrease in differentiation of OPCs was short-term, or whether the changes 
persist at later time-points, i.e. 10 or 15 days after retroviral injection. 
5.2.4. Effects of acute modification versus chronic deletion of AMPARs in OPCs. 
Up to now several studies in cell culture, in vitro, and in vivo indicated that signal transmission 
through AMPARs in OPCs may affect differentiation and proliferation of OPCs [33, 82, 95, 99]. 
However, a recent study in mice in vivo has shown that double knock-out of Gria2/3, the genes 
encoding for GluA2 and GluA3 subunits of AMPARs respectively, reduced AMPARs-mediated 
signaling in OPCs, and the triple knock-out of Gria2/3/4 abolished this signaling but neither of 
these modifications caused changes in proliferation of OPCs [65]. Yet, double and triple knock-
out of AMPARs subunits in OPCs resulted in the reduced numbers of myelinating OLs, 
indicating that AMPAR-mediated signaling is important for  survival of oligodendrocyte lineage 
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cells [65]. Knock-out of either Gria2 or Gria3 alone did not influence differentiation and 
proliferation of OPCs [65]. The findings of my study differ from the results of Kougioumtzidou 
et al. [65]. There may be several reasons for these differences. First, in the study of 
Kougioumtzidou et al. [65], ablation of single or multiple AMPAR subunits from the onset of 
mouse development may have initiated the compensatory pathways in the glutamatergic 
signaling, or in the regulation of proliferation and lineage progression of OPCs. On the contrary, 
I perturbed the AMPAR-mediated signaling after the neuron-OPC synaptic connections have 
been already established. This experimental approach may allow less time for compensatory 
effects to be switched on. Second, using our approach I did not delete the gene regulating 
expression of the endogenous GluA2 subunit. Therefore, the endogenous GluA2 subunit may 
have played a role in preventing the excitotoxic death in OPC [140-144]. Third, OPCs 
investigated in my study may represent a sub-population of OPCs investigated in the study of 
Kougioumtzidou et al. [65]. I used retroviral gene delivery approach to alter AMPAR-mediated 
signaling in OPCs. Retrovirus is known to target cells which are dividing at the time of infection; 
therefore the results observed in my study were from the OPCs which were proliferating at the 
time-point of viral infection. Those proliferating OPCs differentiated and/or underwent the 
second cell division within 5 days. In the study of Kougioumtzidou et al. [65], ablation of 
AMPARs genes was performed in all OPCs regardless of their proliferation status. The 
populations of OPCs may cause the differences. In the future, it would be interesting to 
investigate whether several cell divisions are necessary before an OPC starts differentiation and 
maturation process, and whether a defined time-interval is required between the end of 
proliferation and beginning of differentiation of OPCs. 
Taken together, Ca
2+
 permeability of AMPARs may be one of the mechanisms regulating 
proliferation of OPCs because Ca
2+
-permeable GluA2 constructs (“Ca2+-permeable” and “pore-
dead”) but not C-terminus of GluA2 led to the increase in proliferation. However, Ca2+ 
permeability of AMPARs is not the only mechanism regulating differentiation of OPCs because 
expressing constructs of “Ca2+-permeable”, “pore-dead”, or “C-tail” in OPCs resulted in the 
decrease in their differentiation to OLs.  
Differentiation and proliferation are tightly regulated in OPCs because OPCs have to response to 
the cues for differentiation or proliferation at the right timing. It has been reported that OPCs 
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purified from optic nerve have an “intrinsic clock” to stop the cell division and start the 
differentiation [145]. It is possible that those two processes in OPCs are already programmed 
when OPCs are born. Understanding the mechanisms of differentiation and proliferation in OPCs 
are important because it may help for “re-program” the differentiation and/or proliferation of 
OPCs in the pathological conditions. 
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6. Conclusion. 
In the present study I found that Ca
2+
 signaling through AMPARs at the postsynaptic sites of 
neuron-OPC synapse is important for modulation the differentiation and proliferation of OPCs. 
My data also suggest that non-ionotropic functions of AMPARs may play an essential role in 
regulating differentiation of OPCs. Therefore, activation of AMPARs may trigger several 
pathways which participate in regulation of differentiation and proliferation of OPCs. As 
reported previously, neuronal activity modulates development and function of oligodendrocyte 
lineage cells [18, 82, 94-96], suggesting that alterations at the presynaptic part of axon-OPC 
synapses may play an important role in these processes. I found that the properties of AMPARs 
at the postsynaptic sites can also influence the proliferation and differentiation of OPCs.  
Understanding the mechanisms of GluA2-dependent regulation of proliferation and 
differentiation of OPCs under physiological condition is fundamentally important. Over the long-
term, the results of my study may also be applied to the demyelinating disorders, and may be 
instructive for the development of new therapeutic strategies for these diseases. 
7. Future perspectives. 
In order to understand the relationship between axon-OPC AMPAR-mediated signaling, 
differentiation and proliferation of OPCs, and myelination by OL, in the future it would be 
interesting to investigate the following issues:  
(1) The basic mechanisms of AMPARs trafficking in OPCs; 
(2) The downstream cascades of AMPARs-mediated signaling, and expression of genes which 
are involved in regulation of differentiation and proliferation of OPCs; 
(3) Relationship between different patterns of neuronal activities and function of different 
AMPARs subunits in OPCs. 
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